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ABSTRACT 
 
CHANGES IN PROTEIN PROFILES IN BORTEZOMIB 
APPLIED MULTIPLE MYELOMA CELLS 
 
Multiple Myeloma is a malignant B-cell neoplasm that is characterized by the 
accumulation of malignant plasma cells in the bone marrow. Over the recent years, 
several novel agents have been introduced in the treatment of this disease. Bortezomib 
is the first of a new class of agents known as proteasome inhibitors.  
The main objective of the project was basically to both determine the cytotoxic 
and apoptotic effects of Bortezomib on Multiple Myeloma U-266 cells and compare and 
explore the differences between Bortezomib applied Multiple Myeloma cells and 
control group Multiple Myeloma cells, by proteomics studies. In order to achieve our 
aims in the project, variety of multidisciplinary subjects were come together. Cancer 
research techniques, biochemical studies at protein level and proteomics were combined 
in our studies.  
In this study, our experimental results demonstrated that Bortezomib has 
antiproliferative and apoptotic effects on MM U-266 cells. On the other hand, the 
responsible proteins for the effect mechanism of anti-cancer agent on cells were 
determined by MALDI-TOF-TOF Mass Spectrometry for the first time. According to 
the mass spectrometric analysis, 37 protein spots were differentially expressed. Among 
them, five proteins were newly formed, ten proteins lost, twelve proteins were up-
regulated and ten proteins were down-regulated as compared to control group (untreated 
cells).These differential expressed proteins in response to Bortezomib have different 
important functions ranging from cell signaling transduction, cell cycle regulation, 
apoptosis to immunity and defense mechanism.    
In conclusion, it was identified which proteins have a central role behind the 
effect of Bortezomib on MM U-266 cells. The identified proteins may let to be possible 
to treat other cancer types by same anticancer agent. The data obtained by this study 
may also be helpful for medical schools and drug designers and may also provide new 
treatments.  
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ÖZET 
 
BORTEZOMĠB UYGULANAN  
MULTĠPL MĠYELOMA HÜCRELERĠNĠN 
PROTEĠN PROFĠLLERĠNDEKĠ DEĞĠġĠKLĠKLER 
 
Multilpl Miyelom, bağıĢıklık sisteminin bir parçası olan B hücrelerinin, hasarlı 
olarak kemik iliğinde çoğalması ve birikmesiyle oluĢan hematolojik bir kanserdir. Son 
yıllarda, bu hastalığın tedavisi için birçok yeni kimyasal ajan tıp dünyasınin hizmetine 
sunulmuĢtur. Bortezomib, Multipl Miyelom tedavisinde kullanılan ve tedavi sırasında 
proteazom inhibitörü olarak görev yaptığı bilinen bir anti-kanser ajandır.  
Projenin esas amacı, hem Bortezomibin Multipl Miyeloma hücreleri üzerindeki 
sitotoksik ve apoptotik etkilerini belirlemek hemde Bortezomib uygulanan bu hücreler 
ile control grubu hücreleri arasındaki farklılıkları kıyaslamak ve keĢfedebilmekti. Bu 
projede, hedeflerimize ulaĢmak için, çeĢitli interdisipliner konular biraraya getirilmiĢtir. 
Bu hedef doğrultusunda, kanser araĢtırma teknikleri, protein bazlı biyokimyasal 
çalıĢmalar ve proteomik yaklaĢımlar kombine edilerek kullanılmıĢtır.  
Bu çalıĢmadaki deneysel sonuçlarımız, Bortezomibin, MM U-266 hücreleri 
üzerinde antiproliferatif ve apoptotic etkilere sahip olduğunu gösterdi. Öte yandan, bu 
anti-kanser ajanın hücreler üzerindeki etki mekanizmasında görev alan proteinler 
MALDI-TOF-TOF Kütle Spektrometresi ile ilk defa belirlenmiĢtir. Kütle 
spektrometresi sonuçlarına gore, otuz yedi protein spotunda farklılık gözlenmiĢtir. 
Bunlardan beĢ spot yeni oluĢan ve on spot kaybolan proteinlere karĢılık gelmiĢtir. 
Ayrıca, on iki spotun seviyesinde artıĢlar gözlenirken, on ayrı spotun da ekspirasyon 
seviyelerinde azalma gözlenmiĢtir. Bu proteinler hücre içerisinde, sinyal iletiminden, 
hücre bölünmesine, apoptozdan vücudun savunma mekanizmasına kadar değiĢen 
önemli fonksiyonlara sahipler. 
Sonuç olarak Bortezomibin MM U-266 hücreleri üzerindeki etki 
mekanizmasında hayati öneme sahip proteinler tanımlanmıĢtır. Farklılık gösteren bu 
proteinlerin ve fonksiyonlarının belirlenmesi sayesinde aynı kemoterapatik ajan ile aynı 
proteinlerin rol aldığı diğer kanser türlerinin de tedavi edilebilirliği mümkün olabilir. 
Ayrıca buradan elde edilen bulgular, yeni tedavi yöntemleri konusunda tıp fakültelerine 
ve ilaç dizaynı üzerine çalıĢan araĢtırmacılara yeni ufuklar açabilir.  
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CHAPTER 1 
 
INTRODUCTION TO MULTIPLE MYELOM 
 
1.1. Cancer 
 
Cancer is one of the most frightning health problems of our age on account of 
higher death rate. It is known that the number of research groups dealing with the 
biological basis of cancer formation, progression and new treatment options increase in 
number with the expansion of the knowledge in the field of cancer research, but, 
unfortunately, cancer still remains one of the leading causes of death after the 
cardiovascular diseases in the world (Jemal et al., 2007). According to GLOBOCAN 
2008 data, nowadays, approximately 12 million people worldwide caught this disease 
each year, about 7 million of these patients (~60%) are dying in the same year and it is 
estimated that 25 million cancer patients are still alive (Bilir, 2008; Jemal et al., 2011). 
Furthermore, considerable number of scientific studies on cancer statistics show that 
both the rate of cancer is increasing day by day and diagnosis and treatment options of it 
require the co-operation of many specialized fields (Parkin et al., 2005; Boyle and 
Levin, 2008; Jemal et al., 2011 respectively).  
The term cancer applies to a set of diseases characterized by unregulated, 
abnormal cell growth leading to invasion of surrounding tissues from its point of origin 
and spreads to other parts of the body where they establish secondary areas of growth 
(King and Robins, 2006; Lieberman and Marks, 2009). A brief definition for cancer 
would be a group of diseases in which cells no longer respond to normal restraints on 
growth. In other words, cancer originates from the loss of normal growth control.  
The body is made up of hundreds of millions of living cells. Normal body cells 
grow, divide and die in an orderly fashion. During the early years of a person's life, 
normal cells divide faster to allow the person to grow. After the person becomes an 
adult, most of the cells divide only to replace worn-out or dying cells or to repair 
injuries and the rates of new cell growth and old cell death are kept in balance. On the 
contrary, cancer cell growth is very different from normal cell growth. Instead of dying, 
cancer cells continue to grow and form new, anomalous cells. 
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When normal cells in the body begin to divide for proliferation to replace the 
death ones, two or more cells begin to come into contact with each other to slow up the 
rate of division. This behaviour is a consequence of the natural process of arresting cell 
growth called contact inhibition. It is one of the most significant control mechanism to 
direct the cells to stop proliferating and it ensures the cells to create a layer only one 
cell thick, a monolayer (Alberts et al., 2008; Lieberman and Marks, 2009; NCI, 2011).  
On the other hand, the behaviour of cancer cells is quite different. These cells do 
not require growth stimulatory signals and also they are resistant to growth inhibitory 
signals. When the normal cells regulate the growth, unfortunately, cancer cells continue 
to divide in an unregulated manner yielding a clump of cells which is called focus. So, 
the balance between formation and destruction of cells is disrupted. Moreover, cancer 
cells are also resistant to apoptosis (programmed death process) which is the 
mechanism by which old or damaged cells normally self-destruct. They have an infinite 
proliferative capacity and do not become senescent (ġenel and Çırakoğlu, 2003; Alberts 
et al., 2008; Lieberman and Marks, 2009; NCI, 2011).  
All of these data introduce the linked questions : What agents cause cancer? 
What is the reason of abnormal growth of cancer cells? and How does cancer develop? 
Although there are multiple risk factors including genetic (biological) factors, 
age, obesity, declining immune system, exposure to chemicals and/or radiation, 
pesticides and virus, environment and lifestyle factors are known to have a major 
impact to constitute the cancer. Relevant research demonstrates us that of all cancer-
related deaths, nearly 5-10% are due to genetic factors, whereas the rest of it, nearly 90-
95% are because of lifestyle and environment factors (Anand et al., 2008; Irigaray et 
al., 2007). 
The aberrant growth pattern in cancer stems from many mutations in genes 
which are responsible for proliferation, differentiation and survival of cells. Cancer cells 
no longer respond to growth inhibitory signals owing to these genetic changes 
(Lieberman and Marks, 2009). In Figure 1.1, the difference between normal cells and 
cancer cells in terms of growth control mechanism can be seen easily. DNA is in every 
cell and directs all its actions. In a normal cell division, when a cell’ s DNA gets 
damaged, the cell either repairs the damage or goes to apoptosis (programmed cell 
death) yet, in cancer cell division, the damaged DNA is not repaired, make matters 
worse, the cell does not die like it should. Instead, this cancer cell goes on making new 
copies that the body does not need. These new cells will all have the same damaged 
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DNA as the first cell does. Therefore, if mutation is not repaired properly and before 
replication occurs, the mutated cells amplify to generate billions of cells that constitute a 
cancer (King and Robins, 2006; Lieberman and Marks, 2009).  
 
 
Figure 1.1. Loss of Normal Growth Control 
 
Carcinogenesis, the process by which cancers are developed, is a multistage 
mechanism resulting from the accumulation of errors in vital regulatory pathways. It is 
initiated in a single cell, which then multiplies and obtains additional alterations that 
give it a survival advantage over its neighbours (Figure 1.2) (King and Robins, 2006).  
Figure 1.2 represents development of cancer. Each connecting arrow refers 
several events and many pathways can exist between each stage. First step (Initiation) 
explains the generation of mutated cells in consequence of mutations. Following step 
(Promotion) expresses the proliferation of differentiated cells. Step three (Progression) 
states the formation of cancer. Subsequent to this uncontrolled growth, cancer cells that 
alter morphological properties, invade other tissues and metastasize. 
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Figure 1.2. Development of Cancer 
 
Six considerable characteristics found in cancer cells are called hallmarks of 
cancer (Hanahan and Weinberg, 2000). They are as follows : 
 
 Self-sufficiency in growth signals, 
 Insensitivity to antigrowth signals, 
 Evasion of apoptosis, 
 Limitless replicative potential, 
 Sustained angiogenesis, 
 Tissue invasion and metastasis. 
 
1.2. Multiple Myeloma (MM) 
 
Multiple Myeloma (MM) (also known as myelomatosis, plasma cell myeloma 
or Kahler's disease) is a malignant B-cell neoplasm that is characterized by the 
accumulation of malignant plasma cells in the bone marrow. It is known as bone 
marrow cancer in the society and it is the second most common hematological disorder 
(Raab et al., 2009). It accounts for 2% of cancer deaths among the most dangerous 
cancer types (Zaidi and Vesole, 2001). Recently, increasing number of people is being 
diagnosed as MM. It has a yearly incidence of nearly 14-15 thousand that accounts for 
approximately 10% of all hematologic cancers in the US (San et al., 1999; Collins, 
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2005) and the incidence number is almost 3 thousand in Turkey (Lag et al, 2002; 
Horner et al., 2009). In addition to all of this statistic data, American Cancer Society 
reports that approximately 20 thousand new cases of MM is diagnosed during 2008 
(NCI, 2011).  
As mentioned before, MM is a type of cancer formed by malignant plasma cells. 
Plasma cells mainly take part in the bone marrow which is the soft tissue found inside 
some hollow bones. These cells are an important part of the immune system.  
Even though immune system is composed of several types of cells that 
endeavour together to fight infections and other diseases, lymphocytes (lymph cells) are 
the main cell type of it. They can be found in many areas, such as lymph nodes, bone 
marrow and bloodstream. There are two types of lymphocytes; T cells and B cells.  
When B cells respond to an infection, they are activated by helper T cells (CD4 
T Cells) in the presence of IL-4, IL-5, IL-6 (cytokines) and CD40 Ligand. These 
activated B cells mature and change into memory cells and plasma cells (Figure 1.3) 
(Murphy et al., 2008). Plasma cells are responsible for the making antibodies 
(immunoglobulins, a kind of protein) that help the body protect from germs and other 
harmful substances by attacking and killing them (Figure 1.4) (NCI, 2011). 
 
 
Figure 1.3. The Activation and Differentiation of B Cell 
(Source: Murphy et al., 2008) 
 
In MM, the body makes too many plasma cells (myeloma cells) (Bataille and 
Harousseau, 1997). These cells lose their normal functions and produce much more 
antibodies called M proteins that the body does not need. Myeloma cells at issue cause 
the problems in the body in two ways: They crowd out the normal plasma cells so that 
the antibodies to fight the infections are not made. Additionally, antibodies secreted by 
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the myeloma cells does not help fight infections. That is why, it should not be expected 
from this abnormal plasma cells to protect the body. 
 
 
Figure 1.4. Function of the Plasma Cells 
(Source: NCI, 2011) 
 
1.2.1. The Classification of MM 
 
Different types of myeloma can be classified into three parts by the type of 
antibody (immunoglobulin, also called M protein) secreted by malignant plasma cells. 
  
 Plasma cells can produce a certain types of immunoglobulin (such as 
IgG), 
 Plasma cells can produce incomplete immunoglobulins, containing only 
the light chain portion of it, 
 Plasma cells do not produce immunoglobulins or light chains.  
 
Immunoglobulins (Ig) can be classified under the category of glyco-proteins and 
basically made up of two components; light chains (which has 25 kDa molecular weight 
and consists of 220 amino acids) and heavy chains (which has 50 kDa molecular weight 
and consists of 220 amino acids) (Voet et al., 1999). What is more, they are classified 
by the sort of light (kappa or lambda) or heavy (alpha [IgA], gamma [IgG], mu [IgM], 
delta [IgD], and epsilon [IgE]) chains, based on differences in the amino acid sequences 
in the constant region of the light or heavy chains. (Steward, 1984).  
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The main molecular structure of immunoglobulins is shown in Figure 1.5. Even 
though antibodies can differ structurally, they are made from the same basic unit (Voet 
et al., 1999). Light and heavy chain immunoglobulins show a Y shape structure 
(Steward, 1985). 
 
 
Figure 1.5. Molecular Structure of Immunoglobulin 
(Source: Voet et al., 1999) 
 
Although MM cells can produce all classes of immunoglobulins theoretically, 
IgM type immunoglobulin is the least and IgG kappa is the most common monoclonal 
protein encountered in MM. Approximately 60% to 70% of all cases of MM is IgG 
type. Morover, IgA type of MM accounts for about 20% of cases. As compared to IgG 
type, IgA myeloma cells are less widespread, but still prevalent. IgD and IgE types MM 
are very rare (Anderson, 2003; Sirohi and Powles, 2004;  Multiple Myeloma, 2011). 
Some cells produce an incomplete immunoglobulin consisting of only light 
chains, known as Bence-Jones proteins (Light Chain Myeloma or Bence Jones 
Myeloma). Most of the time it is seen in the form of kappa, but it can be also lambda 
type (Hoffbrand et al., 2006; Putnam and Stelos, 2011). In this disease, M protein is 
found primarily in the urine, rather than in the blood. On the other hand, some rare 
diseases are associated with plasma cell overproduction of heavy chains only. These are 
called as heavy chain diseases and they may or may not be similar to myeloma in their 
characteristics.  
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A rare form of MM called Nonsecretory Myeloma occurs in about 1% of 
myeloma patients. In this disease, neoplastic plasma cells do not produce any 
immunoglobulin chains, heavy or light (Shaw, 2006). 
 
1.2.2. Molecular Pathways of MM 
 
MM is a plasma cell malignancy characterized by very complex cytogenetic and 
molecular genetic aberrations.  
Cancers can be caused by mistakes, defects or certain changes in the DNA 
called mutations that turn on oncogenes or turn off tumor suppressor genes. DNA is a 
complex molecule and the fundamental building block for a human's entire genetic 
makeup. It is a component of virtually every cell in the body. Certain genes that are the 
parts of the DNA and responsible for promoting cell division are called oncogenes and 
others that take charge in slowing down cell division or causing cells to die at the 
appropriate time are known tumor suppressor genes.  
Chromosomal translocations and/or point mutations, amplifications of proto-
oncogenes and inactivations of tumor supressor genes are the important mechanisms 
that cause to progression of MM. Oncogenes which are active in this disease and their 
activation mechanisms are shown in the Table 1.1 (Gahrton and Durie, 1996). 
 
Table 1.1 Genetic Alterations in MM 
Oncogenes Chrosomal 
Locations 
Activation 
Mechanism 
Literatures 
c-myc 8q24 Trasnlocation 
(Greil et al., 1991), 
(Cobbold et al., 2010) 
bcl-2 18q21 Trasnlocation  (Pettersson et al., 1992) 
N-ras 1p11-13 Point Mutation (Portier et al., 1992) 
K-ras 12p11-12 Point Mutation (Portier et al., 1992) 
p53 17p13 Point Mutation 
Deletion 
(Neri et al., 1993),  
(Portier et al., 1992) 
Rb1 13q14 Deletion  (Gahrton and Durie, 1996). 
c-MAF 
14q16 or 
14q20 
Trasnlocation 
(Sawyer et al., 1998) (Kuehl 
and Bergsagel, 2002) 
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In MM, a chromosomal translocation between the immunoglobulin heavy chain 
gene on chromosome 14, locus q32 (14q32) and an oncogene 11q13 (cyclin D1), 4p16 
(FGFR3 & MMSET (Multiple Myeloma SET Domain)), 6p21 (cyclin D3), 16q23 (c-
maf), 20q11 (mafB) and 8q24 (mafA), which account for about 40% of all myeloma 
tumors (Table 1.2), (Bergsagel and Kuehl, 2001; Barillé-Nion et al., 2003; Kyle and 
Rajkumar, 2004) is frequently observed. These mutations bring about disregulation of 
the oncogenes that are known to be a significant initiating event in the pathogenesis of 
MM. The consequence all of these mutations is proliferation of a plasma cell clone and 
genomic instability that leads to further mutations, deletions and translocations.  
 
Table 1.2. Prevalance of Important Translocations in MM (Adapted from Sawyer et al., 
1998; Kuehl and Bergsagel, 2002; Avet-Loiseau et al.,2002). 
 
Translocations Prevalance 
11q13 (cyclin D1) 15% 
4p16 (FGFR3 & MMSET) 15% 
6p21 (cyclin D3) 3% 
16q23 (c-maf) 4% 
20q11 (mafB) 2% 
8q24 (mafA) 1% 
TOTAL 40% 
 
Translocations between t(4;14) (p16;q32) or t(14;16) (q32;q23), partial (q14) or 
complete loss of chromosome 13 and partial loss of 17p13 refer to high risk of MM 
(Stewart and Fonseca, 2005; Tassone et al., 2006). In addition to these data, 
translocation t(11;14) (q13;q32) that is activated Bcl-1 oncogene is the most common 
chromosomal difference (Stewart, 2008). This translocation is also seen in other 
hematological cancers. Besides, changes in the number of chrosomes are frequently 
encountered in MM, especially hyperdiploidy is seen at the 3., 5., 7., 9., 11., 15., 19. 
and 21. chromosomes whereas hypodiploidy is seen at the 8., 13. and X chromosomes 
(Gahrton and Durie, 1996; Mahindra et al., 2010). 
In MM, the chromosome 14 abnormality is observed nearly 50% of all cases of 
myeloma and aberration of chromosome 13 is also observed in about 50% of cases with 
85% monosomy 13, while the remaining 15% constitute deletion of chromosome 13 
(Munshi and Avet-Loiseau, 2011; Sawyer, 2011). 
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1.2.3. Risk Factors for MM 
 
A risk factor can be defined as anything which alterates a person's chance of 
getting the disease. 
The known risk factors for MM are as follows ;  
Age is the most crucial risk factor for MM, as nearly 98% of cases are 
diagnosed in people over the age of 40. It means that only 2% of patients are younger 
than 40 years old. Furthermore, more than 75% of these patients over the age of 70. 
Median age for men is about 62 years and for women 61 years at diagnosis (Raab et al., 
2009).  
 It is thought that susceptibility to get MM may increase with the aging process. 
Because it affects the the people in a negative way in terms of the result of reduction in 
immune surveillance of evolving cancer or accumulation of toxic substances. So, the 
risk of the catching MM goes up with age. 
MM has two times more common incidence in men than in women. Thus, men 
are slightly more likely to develop this disease when compared to women (Mitsiades et 
al., 2004; Sirohi and Powles, 2004).   
Race is also risk factor for MM. It is almost twice as common among African 
Americans than white Americans. The higher incidence of MM in African Americans 
and the much less frequent occurrence in Asians refer genetic factors (Cohen et al., 
1998; Malpas et al., 1998).  
Exposure to radiation may increase the risk of multiple myeloma (ACS, 2011).  
People who has a sibling or parent with MM is four times more likely to 
constitute cancer than would be expected. Still, most patients have no affected relatives, 
so this accounts for only a small number of cases (ACS, 2011).   
Some studies have suggested that people in agricultural occupations, workers 
both in certain petroleum-related industries and leather industries and cosmetologists all 
seem to have a higher-than-average chance of developing MM. Exposure to herbicides, 
insecticides, petroleum products, heavy metals, plastics and various dusts including 
asbestos also appear to be risk factors for the disease. In addition, people exposed to 
large amounts of radiation, such as survivors of the atomic bomb explosions, have an 
increased risk for MM, although this accounts for a very small number of cases (ACS, 
2011).   
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 Obesity is the most common known risk factor for MM. Being overweight or 
obese increases a person’s risk of developing MM according to a study carried out by 
the American Cancer Society (ACS, 2011).    
Other plasma cell diseases are also important risk factor for people, because 
these people most prone to get caught to MM. There is a crucial information related to 
plasma cells and MM. It must be noted that uncontrolled plasma cell growth is not 
always correspond to MM. Besides, there are two plasma cell related diseases like MM. 
One of them is monoclonal gammopathy of undetermined significance (MGUS). 
In this diseases, similar to MM, abnormal plasma cells produce excess amounts of 
antibody protein. However, these cells do not form an actual tumor or mass and do not 
cause any of the other problems seen in MM. The most distinction between MGUS and 
MM is that MGUS does not give rise to weak bones and anemia.  
Scientists who have studied the genes of the plasma cells in patients with MGUS 
found that the genetic background of these cells resembles myeloma plasma cells more 
than it resembles normal plasma cells. This finding suggests that these cells are 
principally malignant, and people with MGUS can go on to develop MM (Weiss and 
Kuehl, 2010).  
Another type of abnormal plasma cell growth disease is solitary or isolated 
plasmacytoma. It differs from MM with regards to number of tumor. Patients with this 
disease have only one tumor rather than multiple tumors in different locations as in 
multiple myeloma. Most often, a solitary plasmacytoma develops in a bone, but it is 
also rarely found in other tissues. When it begins in other tissues (such as the lungs), it 
is called an extramedullary plasmacytoma. As many people with a solitary 
plasmacytoma will develop multiple myeloma (Di Micco and Di Micco, 2005). 
 
1.2.4. Signs and Symptoms of MM 
 
The bone marrow microenvironment has a key role in both bone destructive and 
tumor growth process in MM (Roodman, 2009). There are two major kinds of bone 
cells that basically work together to keep bones healthy and strong. One of them is 
osteoblasts that are responsible for laying down new bones and the other one is 
osteoclasts which break down worn or dying bones. These cells take part in the bone 
tissue. The main function of osteoblasts are both bone matrix synthesis and regulation 
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of the mineralizations by adjusting the calcium-phosphorus balance. The most 
characteristic morphological features of osteoclasts are their curved cell edges and 
finger-shaped cell membrane protrusions. These features makes it easy to form bone 
resorption (the destruction of bones from metabolism by melting physiologically). 
function. These two types of cells are controlled various growth factors and they are in 
balance in the bone tissues of healthy individuals. However, this situation is somewhat 
differ in patients with MM. Because myeloma cells change the balance between 
osteoblasts (formation of new bones) and osteoclasts (destruction of old bones) in favor 
of osteoclasts by producing certain growth factors. While dickkopil, interleukin-3 (IL-3) 
and interleukin-7 (IL-7) which are the growth factors secreted by myeloma cells are 
inhibiting the functions of osteoblast cells, macrophage inflammatory protein and 
interleukin-3 (IL-3) activate the role osteoclast cells either directly or indirectly (Terpos 
and Dimopoulos, 2005; Silvestris et al., 2007; Terpos, 2008) (Figure 1.6). Another 
important molecule in bone metabolism, RANKL (Receptor Activator for Nuclear 
Factor KB Ligand), plays also a role to activate the osteoclasts (Edwards et al., 2008). 
In addition to all of these, myeloma cells encourage the bone marrow stromal cells to 
the production of interleukin-6 (IL-6), interleukin-1 (IL-1) and Tumor Necrosis Factor 
(TNF) to increase osteoclast formation and tumor growth (Sirohi and Powles, 2004; 
Terpos, 2008; Roodman, 2009). These interleukins activates multiple pathways that 
protect myeloma cells from apoptosis (Zaidi and Vesole, 2001; Bommert et al., 2006). 
 
 
 
 
 
 
 
 
 
Figure 1.6. Tumor-micro Environmental Interactions in MM 
(Source: Roodman, 2009) 
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As a result of this situation observed in patients with MM, bones are damaged 
causing pain and sometimes they can even break. Fractured bones and bone pain which 
is leading manifestation of myeloma in 75% of MM patients (Zaidi and Vesole, 2001)) 
are major problems.  
Another significant symptom of MM is high blood calcium. With the increased 
bone resorption, calcium in the bones is released. This can result from high blood levels 
of calcium (hypercalcemia) that can cause dehydration, severe constipation, loss of 
appetite, drowsy and nausea. Furthermore, renal failure (present 5-30% of MM 
patients) may commonly develop owing to hypercalcemia both acutely and chronically 
(Alexanian et al., 1990; Ludwig, 2005; Smith et al., 2006; Wirk, 2011; ACS, 2011).  
One of the reason for MM patients to feel themselves very tired and weak is 
anemia that blocks the proliferation of the new red blood cells by malignant myeloma 
cells. A reduced number of red blood cells causes weakness, shortness of breath and 
dizziness. Furthermore, they also hamper the formation of new white blood cells which 
are significant for immune system. This is why, insufficient white blood cells 
(leukopenia) lowers resistance to infections (Zaidi and Vesole, 2001) and the lower 
blood platelet (thrombocytopenia) (Kristinsson, 2010) may cause serious bleeding 
(Ludwig, 2005; ACS, 2011). 
Patients with MM are nearly fifteen times more likely to get infections. This is 
because, the body is unable to make the antibodies which help fight infection. One of 
the result of this situation, patients are slow to respond to treatment. Pneumonia is very 
common and a serious infection determined in myeloma patients (Savage et al., 1982; 
ACS, 2011). 
 If MM give rise to the weakening of bones in the spine, they can press on spinal 
nerves causing sudden severe pain, numbness, and/or muscle weakness. Besides, some 
abnormal proteins produced by myeloma cells can be toxic to the nerves.  
 
1.2.5. Diagnosis of MM 
 
For the diagnosis of MM, many test and procedures were introduced with the 
clinic. These crucial studies in terms of the evaluation of MM, their purposes and results 
are demonstrated in Table 1.3.  
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To measure the levels of red cells, white cells, and platelets in the blood, the 
complete blood count (CBC) test can carry out. As myeloma cells occupy too much of 
the bone marrow, CBC levels in patients body will be low. 
So as to assess the blood levels of the different antibodies the test quantitative 
immunoglobulins can perform. In these test, the levels of immunoglobulins quantified 
to observe if any of them are anomalously high or low. According to previous studies, 
we know that the level of one type immunoglobulin may be high while the others are 
low in MM. 
Other laboratory tests to find any abnormal immunoglobulin and measure the total 
amount of it are Serum Protein Electrophoresis (SPEP) and urine protein 
electrophoresis (UPEP). Besides, immunofixation or immunoelectrophoresis and urine 
immunofixation can be carried out in order to detect the which type of antibody is 
abnormal (Smith et al., 2006). 
When the SPEP results are inadaquate, the test  that is based on quantifying the 
lighy chains can be used in certain types of myeloma (Bradwell et al., 2003).  
 
Table 1.3. Laboratory Tests and Procedures to Diagnose the MM 
(Source : MMRF, 2010) 
 
BLOOD SPECIMEN 
Diagnostic Test Purpose Results 
Complete blood count  
(number of red blood cells, 
white blood cells, platalets and 
relative proportion of white 
blood cells) 
 
Determine the degree to which 
myeloma is interfering with the 
normal production of blood cells 
 
Low levels may signal anemia 
increased risk of infection and 
poor clotting 
Chemistry profile  
(albumin, calcium lactate 
dehydogenase (LHD), blood 
urea nitrogen (BUN), and 
creatinine) 
 
Assess general health status and 
the extent of disease 
 
 
Abnormal levels may indicate 
kidney damage and increased 
size/number of tumors 
Beta2- microglobulin (B2-M) 
level 
Determine the level of serum 
protein that reflect both disease 
activity and renal function 
Higher levels indicate more 
extensive disease; aids in 
staging of disease 
C- reactive protein 
Obtain an indirect measure of 
the number of cancer cells 
Higher levels indicate more 
extensive disease 
 
Immunoglobulin levels 
Define the levels of antibodies 
that are overproduced by 
myeloma cell 
Higher levels suggest the 
presence of myeloma 
 
                                                                                                                     (cont. on next page) 
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Table 1.3. Laboratory Tests and Procedures to Diagnose the MM (cont.) 
BLOOD SPECIMEN 
Diagnostic Test Purpose Results 
 
Serum protein electrophoresis 
Detect the presence and level of 
various proteins, including M 
protein 
Higher levels indicate more 
extensive disease; aids in 
classification of disease 
Immunofixation 
electrophoresis (IFE; also 
called immunoelectrophoresis) 
Identity the type of abnormal 
antibody proteins in yhe blood 
 
Aids in classification of disease 
Freelite
TM
 serum free light 
chain assay 
Measure immunoglobulin light 
chains 
Abnormal levels and/or ratio 
suggest the presence of 
myeloma or a related disease 
URINE SPECIMEN 
Diagnostic Test Purpose Results 
Urinalysis Assess kidney function 
Abnormal findings may suggest 
kidney damage 
Bence Jones protein level 
(performed on 24 hour 
specimen of urine) 
Define the presence and level of 
Bence Jones protein 
Presence indicates disease, and 
higher levels indicate more 
extensive disease 
 
Urine protein and 
immunoelectrophoresis 
Determine the presence and 
levels of specific proteins in the 
urine, including M protein and 
Bence Jones protein 
 
Presence of M protein or Bence 
Jones protein indicates disease 
BONE / BONE MARROW SPECIMEN 
Diagnostic Test Purpose Results 
Imaging studies (bone) survey, 
x-ray, magnetic resonance 
imaging (MRI), computerized 
tomograph (CT), positron 
emission tomography (PET) 
Assess changes in the bone 
structure and determine the 
number and size of tumors in 
the bone 
 
 
- 
 
Biopsy (on either fluid aspirated 
from the bone marrow or on 
bone tissue) 
Determine the number and 
pecentage of normal and 
malignant plasma cells in the 
bone marrow 
Presence of myeloma cells 
confirms the diagnosis, and 
higher percentage of myeloma 
cells indicate more extensive 
disease 
Cytogenetic analysis (e.g., 
fluorescence in situ 
hybridization (FISH)) 
Assess the number and 
normalcy of chromosomes and 
identity the presence of 
translocations (mis-matching of 
choromosomes parts) 
Loos of certain chromosomes 
(deletions) or translocations 
may be associated eith poor 
outcome 
 
 
Beta-2 microglobulin level is very important to understant the how much disease 
progress. Actually, this protein is very useful sign for staging of MM. Thus, the level of 
this protein produced by the malignant plasma cells can be evaluated by a test (Bataille 
et al, 1992). 
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 The levels of blood urea nitrogen (BUN) and creatinine levels in blood is 
related with the kidney function. The increased levels of them mean that kidney 
function is impaired. Similarly, low levels of Albumin and high levels of Calcium in 
the blood can be a cue of advanced myeloma (Bataille et al., 1992; Jacobson et al., 
2003). 
Bone marrow biopsy is of great importance in terms of checking the bone 
marrow. Because, in MM, patients have too many plasma cells in their bone marrow 
(Smith et al., 2006).   
With the progression of technology in imaging area, these types of studies begin 
to occupy a great place. One of these types of study is Bone x-rays. By the help of 
method, bone destruction caused by the myeloma cells can be detected (Ozaki, 2007). 
The computed tomography (CT or CAT) scan can be used as an improved x-ray 
procedure to take the detailed cross-sectional images of patient’s body to determine the 
damaged bones (Schreiman et al., 1985; Kyle et al., 1985; Winterbottom and Shaw, 
2009). One another imaging methos is magnetic resonance (MRI). It can be also useful 
in looking at bones. It differs from the x-rays and CT in that it utilizes radio waves 
instead of x-rays. Firstly, this energy is absorbed and then released in a pattern 
produced by the type of tissue. Next, the pattern of radio waves given off by the tissues 
are translated into detailed image of the body (Joffe et al., 1988; Lecouvet et al., 2001).  
To make a diagnosis of MM, results obtained any single test are not sufficient.  
 
1.2.6. Stages of MM 
 
Staging process is very significant in that it is the sign of cancer progress. 
Importance of this process stems from determining the appropriate treatment options 
and prognosis.  
MM has been staged with two systems up to now. One of them is Durie-Salmon 
Staging System and the other one is International Staging System. Although some 
doctors still use this system, its value is becoming restricted due to newer diagnostic 
methods. Recently, International Staging System for MM has been developed.  
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1.2.6.1. The Durie-Salmon Staging System  
 
The Durie-Salmon Staging System was developed in the mid-1970s and most 
commonly used staging system for patient with MM (Jacobson et al., 2003). 
This system is basically depends on four factors ; 
  
 The amount of abnormal monoclonal immunoglobulin in the blood or 
urine, 
 The amount of calcium in the blood,  
 The amount of hemoglobin in the blood, 
 The severity of bone damage based on x-rays.  
  
Table 1.4. Durie-Salmon Staging System in MM 
(Source : Durie and Salmon, 1975) 
 
Stage Criteria 
 
 
I 
 
 
 
I 
Hemoglobin level > 10 g / 100 ml,  
(Hemoglobin level is slightly under the normal level) 
Calcium levels in blood ≤ 12 mg / 100 ml,  
(Normal calcium levels in blood) 
Normal bone structure, 
(Bone x-ray results either appear normal or indicate that  
only one area of bone damage) 
Relatively low monoclonal immunoglobulin rates  
in blood or urine ; 
 IgG value < 5 g / 100 ml  
 IgA value < 3 g / 100 ml 
 Urine light chain monoclonal immunoglobulin  
on electrophoresis < 4 g / 24 hours. 
II A moderate number of malignant plasma cells are present.  
Features of this stage are between stage I and III. 
 
 
 
 
 
 
III 
Hemoglobin level > 8.5 g / 100 ml,  
(Low hemoglobin level) 
Calcium levels in blood > 12 mg / 100 ml, 
(High calcium levels in blood) 
Advanced lytic bone lesions  
(Bone x-ray results indicate that three or more areas of bone) 
High monoclonal immunoglobulin rates  
in blood or urine ; 
 IgG value > 7 g / 100 ml  
 IgA value > 5 g / 100 ml 
 Urine light chain monoclonal immunoglobulin  
on electrophoresis > 12 g / 24 hours. 
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By using the system introduced by Durie and Salmon (Durie and Salmon) in 
1975, MM has been divided myeloma into three stages. According to this system, the 
risk of MM increases from Stage I to Stage III. Thus, Stage I indicates the smallest 
amount of tumor and stage III indicates the largest amount of tumor. 
Large amounts of abnormal monoclonal immunoglobulin is an indicator of 
many malignant plasma cells and advanced MM. 
The amount of calcium in the blood is directly related to bone destruction. 
Because, bones normally include lots of calcium. With the bone damage in MM, 
calcium in the bones are released into the blood. Multiple areas of bone damage seen on 
x-rays indicate an advanced stage of multiple myeloma. 
Hemoglobin level is another important factor to stage MM. It is mainly 
responsible for carrying oxygen and the substance of red blood cells. In MM, malignant 
plasma cells occupy much of the bone marrow, in connection with this, the normal 
bone marrow cells have not enough space to produce red blood cells adaquately. 
Therefore, low hemoglobin level is equal to advanced MM.  
 
1.2.6.2. The International Staging System 
 
The International Staging System is similar to Durie-Salmon Staging System in 
that it also divides MM into three stages. System is based only on the Serum β-2 
Microglobulin and Serum Albumin Levels.  
 
Table 1.5. International Staging System in MM 
(Source : Greipp et al., 2005) 
 
Stage Criteria 
 
I 
Serum β-2 Microglobulin Level < 3.5 mg / L, 
Serum Albumin ≥ 3.5 g / 100 ml,  
 
 
 
II 
Serum β-2 Microglobulin Level < 3.5 mg / L  
but  
Serum Albumin < 3.5 g / 100 ml 
or 
3.5 mg / L < Serum β-2 Microglobulin Level < 5.5 mg / L  
(with any Serum Albumin level) 
III Serum β-2 Microglobulin Level > 5.5 mg / L 
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1.2.7. Treatment Strategy for MM 
 
1.2.7.1. Bortezomib 
 
Treatment strategy for MM is a very important and vital step for the patients, 
because MM is currently still an incurable disease (Pandit, 2005; Dmoszyńska, 2008). 
Bortezomib (Velcade
®
, Millennium Pharmaceuticals Inc., and Johnson & Johnson 
Pharmaceutical Research & Development, LLC) (LCLabs, USA) is the first of a new 
class of anti-cancer agents known as proteasome inhibitor that was entered clinical 
trials and firstly confirmed by the US Food and Drug Administration (FDA) and the 
European Agency for the Evaluation of Medicinal Products (EMEA) for the treatment 
of MM (Mateos and Miguel, 2007).  
Bortezomib (previously known as PS-341, LDP-341, MLN341) is a dipeptide 
boronic acid derivative, which specifically and reversibly inhibit proteasome activity 
and triggers apoptosis in MM by binding the catalytic site of the 26S proteasome with 
high affinity and specificity with the boron atom in its structure (Elliott and Ross, 2001; 
Blade et al., 2003; Richardson et al., 2003; Voorhees et al., 2003; Adams and 
Kauffman,2004; Chauhan et al., 2005). The chemical formula and molecular weight of 
Bortezomib is C19H25BN4O4 and 384.24 g / mol respectively. The chemical structure of 
Bortezomib is as follows (Figure 1.7).  
 
 
Figure 1.7. Structure of Bortezomib 
(Source: Blade et al., 2005) 
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1.2.7.2. Biology of The Proteasome 
 
The 26S Proteasome plays an essential role in the targeted degradation of 
intracellular proteins which are responsible for regulating essential cellular functions, 
such as cell-cycle control, cellular adhesion, proliferation, survival and apoptosis 
(Matthews et al., 1989; Glickman and Ciechanover, 2002). Lots of studies carried out 
using proteasome inhibitors have shown that the 26S proteasome takes charge in the 
elimination of more than 80% of all cellular proteins (Zwickl et al., 1999). 
The proteasome is a 2.5-MDa multi-catalytic proteinase complex present in the 
cytoplasm and nucleus of all eukaryotic cells (Richardson et al., 2003). The primary 
function of this complex is to degrade proteins which have been tagged with a poly-
ubiquitin chain (Adams, 2003; Wolf and Hilt, 2004).  
 
 
Figure 1.8. Scheme of the 26S Proteasome 
(Source: Mateos and Miguel, 2007; Roodman, 2009) 
 
26S proteasome is a cylindrical complex comprised of a 20S catalytic core 
capped at one or both ends by 19S regulatory subunits (Nussbaum et al., 1998; 
Richardson et al., 2003; Voorhees et al., 2003; Blade et al., 2005) (Figure 1.8). The 19S 
regulatory subunits are responsible for binding the poly-ubiquitin chain and cleaving it 
from the protein substrate. They also contain 6 ATPases that are thought to play a key 
role to denature the target protein and might deliver the substrate into the proteolytic 
chamber in the 20S subunit (Zwickl et al., 1999). The 20S catalytic core consists of four 
stacked rings; two outer α-rings that interact with the 19S subunit to check protein entry 
into the 20S catalytic core, and two inner β-rings which makes up of seven β subunits. 
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The β-1, β-2 and β-5 subunits contain the post-glutamyl peptidyl hydrolytic-like, 
tryptic-like, and chymotryptic-like proteolytic activities of the 26S proteasome, 
respectively (Groll et al., 1997) (Figure 1.9).  
 
 
Figure 1.9. Cross Section of β Ring 
(Source: Adams and Kauffman, 2004; Landis-Piwowar et al., 2006; Roodman, 2009) 
 
Proteins entering the 20S catalytic core are degraded in a progressive manner, 
resulting in the release of oligopeptides composing of three to twenty two amino acids 
in length (Goldberg et al., 1997; Hershko and Ciechanover, 1998; DeMartino and 
Slaughter, 1999; Delcros et al., 2003). 
 
 1.2.7.3. Ubiquitin-Proteasome Pathway (UPP) 
 
The degradations process is chiefly mediated by the ubiquitin–proteasome 
pathway (UPP). The binding of ubiquitin to the target proteins from its ε-amine of 
lysine residues involves a series of ATP-dependent enzymatic steps by E1 (ubiquitin-
activating), E2 (ubiquitin-conjugating) and E3 (ubiquitin-ligating) enzymes. This 
combination forms the poly-ubiquitinated protein which serves as substrate for the 
destruction of targeted protein by the proteasome (Glickman and Ciechanover, 2002) 
(Figure 1.10).  
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Figure 1.10. Ubiquitin–Proteasome Pathway (UPP) 
(Source: Mateos and Miguel, 2007) 
 
 1.2.7.4. Proteasome Inhibition by Bortezomib 
 
There is doubtless that inhibition of 26S proteasome affects many vital 
regulatory pathways. Many significant proteins which are regulated by the proteasome 
contain cell cycle regulators p21, p27 and cyclin E (the cyclin-dependent kinase 
inhibitors), pro- and anti-apoptosis factors Bcl-2, Bax, and inhibitory proteins such as 
inhibitor-kappaB (I-κB). All of these proteins are relevant to cancer initiation and 
progression. Accumulation of I-κB on proteasome inhibition induces decreased nuclear 
factor-kappaB (NF-κB) dependent transcription of genes crucial to the promotion of 
tumorigenesis through the induction of cell proliferation and angiogenesis, suppression 
of apoptosis, increasement of tumor cell invasiveness and metastasis (Orlowski and 
Baldwin, 2002; Voorhees et al., 2003; Anderson, 2004).  
The UPP takes an essential role in regulation of the NF-κB family of 
transcription factors. Through the UPP-dependent pathway, NF-κB1 and NF-κB2 are 
processed into their mature forms. Moreover, the activation of NF-κB is dependent on 
proteasome activity (Voorhees et al., 2003). NF-κB is normally sequestered in the 
cytoplasm and rendered inactive by I-κB to hamper its nuclear translocation. However, 
a variety of stimuli, including cell stressors, prompt the phosphorylation of critical 
serine residues on I-κB, targeting it for ubiquitination and proteasomal degradation, 
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which then permits NF-κB to enter the nucleus and mediate transcription. After NF-κB 
translocates to the nucleus, it initiates the transcription of a wide range of genes that 
promote cell survival and growth, influences the expression of cell adhesion molecules 
and cytokine signaling and decreases apoptosis susceptibility. All of these molecules are 
of great significance in cancer progression (Orlowski and Baldwin, 2002; Voorhees et 
al., 2003; Richardson et al., 2003) (Figure 1.11).  
 
 
Figure 1.11. The inhibition of NF-κB activation. 
(Source: Richardson et al., 2003) 
 
The NF-κB pathway is constitutively active in some cancer cells, especially in 
MM. If NF-κB is inhibited by I-κB, cancer development is prevented. The role of 
Bortezomib in NF-κB pathway is to inhibit both NF-κB activation by protecting I-κB 
from degradation by the 26S proteasome and  the adhesion of MM cells to bone marrow 
stromal cells (BMSCs), bringing about blockade of the adhesion related transcription 
and then secretion of multiple cytokines (Chauhan et al., 2005) (Figure 1.12).  
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Figure 1.12. Effect of Bortezomib on Various Growth and Survival Pathways in MM 
(Source: Chauhan et al., 2005) 
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CHAPTER 2 
 
PROTEOMICS AND MASS SPECTROMETRY 
 
2.1. Proteomics 
 
 Proteins are abundant in all organisms and play key roles in most biological 
events as catalysts, transporters, and messengers. Thus, it is crucial to note that all 
research related to proteins increase our understanding of their levels, interactions, 
functions, modifications, regulations, and localization in cells (Graves and Haystead, 
2002; Twyman, 2004). Proteomics is a rapidly expanding discipline that aims to gain a 
comprehensive understanding of proteins. The term proteomics, which is a combination 
of protein and genomics (Figure 2.1), is used to define the large-scale analysis of a 
complete set of proteins, the chief components of cells that are responsible for the most 
significant metabolic pathways in cells or tissues (Wilkins and Pasquali et al., 1996; 
Wilkins et al., 1996; James, 1997; Pandey and Mann, 2000; Graves and Haystead, 2002; 
Lane, 2005).  
 
 
Figure 2.1. Biochemical Interactions Between Genomics and Proteomics 
(Source: Turan and Mohamed, 2011) 
 
The goal underlying proteomics is not only to identify all proteins in a cell, but 
also to identify the correlation between the genetic sequence and three-dimensional 
(3D) protein structure (Graves and Haystead, 2002). In other words, work in proteomics 
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encompasses the investigation of protein-protein interactions, the connection between 
the structure of proteins and their function, cellular processes and networks, and to 
improve protein separation and protein profiling techniques. 
The general workflow (Figure 2.2) in a 2D gel-based proteomics experiment and 
some of the factors affecting the way the experiment is performed are outlined below. 
 
 
Figure 2.2. Schematic of workflow involved in a proteomics experiment, Bio-rad. 
 
2.1.1. Protein Profiling and its Importance 
 
 Protein profiling, an emerging independent subspecialty of proteomics, is poised 
to provide unprecedented insight into biological events. Quantitative evaluation of 
protein levels can be accomplished with protein profiling, which shows us unique 
expression patterns (diseased vs. healthy, treated vs. untreated, experimental vs. control) 
at the protein level when proteins from one cell type are compared with those of another 
cell type. The value of protein profiling is increasing daily and there are several reasons 
why it is of great importance, especially as a potential tool for the early diagnosis of 
leukemias and other diseases. 
 One such reason is that it provides a much better understanding of an organism, 
as it is not always possible or sufficient for scientists to clarify some metabolic 
pathways, including mechanisms of diseases, exclusively by studying the genome 
(Graves and Haystead, 2002). Additionally, there are some difficulties associated with 
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accurately identifying genes solely by dealing with genomic data (Eisenberg, et al., 
2000). To overcome this problem, data provided from genomic studies should be 
supported with data obtained from the study of proteins. Proteomics is often considered 
as the stage following genomics in the study of biological systems. Compared to 
genomics, proteomics is much more complicated, as the proteome differs from cell to 
cell, and under different conditions. This is because distinct genes are expressed in 
distinct cell types, and to identify even a basic group of proteins produced in a cell, one 
needs to have a comprehensive understanding of protein-related actions (Graves and 
Haystead, 2002).  
 Until recently, such research was carried out using mRNA analysis via different 
methods, including microarray technology (Schena et al., 1995; Shalon et al., 1996) and 
serial analysis of gene expression (SAGE) (Velculescu et al., 1995). On the other hand, 
recent studies demonstrate that mRNA analysis can not be correlated directly with 
protein levels (Abbott, 1997; Anderson and Seilhamer, 1997; Gygi et al., 1999; Ideker 
et al., 2001; Dhingraa et al., 2005; Rogers et al., 2008), as mRNA is not always 
translated into proteins (Lane, 2005). Moreover, the quantity of protein formed for a 
given quantity of mRNA depends on both the gene that it is transcribed from and the 
current physiological state of the cell. As such, the level of transcription of a gene 
provides only a rough estimation of its extent of translation into a protein. Additionally, 
mRNA produced may go under rapid degradation that causes a reduction in translation, 
resulting in the production of less protein. In addition, some bodily fluids, such as serum 
and urine, have no source of mRNA under normal circumstances; therefore, proteomic 
technologies have emerged as an important addition to genomic studies (Graves and 
Haystead, 2002).  
 Proteomics verifies the presence of a protein and provides a direct measure of 
the quantity present. An additional important reason that protein profiling is crucial is 
its power to analyze protein modifications. Although a particular cell may have a 
distinguishable set of proteins at various times or under various conditions, any 
particular protein may go through a wide range of alterations known as post-
translational modifications, which will have critical effects on its function. 
Phosphorylation is an example of posttranslational modification. Structural proteins can 
undergo phosphorylation during cell signaling and result in the protein becoming a 
target for binding to or interacting with a distinct group of proteins that recognize the 
phosphorylated domain (Hunter, 1995). Ubiquitination is another post translational type 
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of modification. Ubiquitin is a small protein that can be affixed to certain protein 
substrates by means of enzymes known as E3 ubiquitin ligases (Glickman and 
Ciechanovr, 2002). Identifying which protein is poly-ubiquitinated can be helpful in 
understanding how protein pathways are regulated. In addition to phosphorylation and 
ubiquitination, proteins can undergo additional modifications via methylation, 
acetylation, glycosylation, oxidation, sulfation, hydroxylation, nitrosylation, amidation, 
etc. 
 These modifications can be assessed only at the protein level and modifications 
of many proteins expressed by a cell can be determined at the same time using such 
proteomic methods as phosphoproteomics and glycoproteomics (Graves and Haystead, 
2002). In addition to modifications, there is no doubt that protein localization and 
interactions are of vital importance to their function. Mislocalization of a protein or any 
problem in signal transduction can turn normal cells into abnormal cells, which is a 
well-known paradigm in carcinogenesis. Protein profiling using proteomic methods can 
also be used to characterize these regulatory mechanisms. Another point that 
emphasizes the importance of protein profiling is that many proteins form complexes 
with other proteins and/or with nucleic acids, and exert their function in the presence of 
these molecules. 
 In summary, protein profiling provides a much better understanding of an 
organism, in terms of structure and function. Use of protein profiling in the study of 
multiple proteins, protein forms, and protein families, almost always by comparing two 
different states (diseased vs. healthy), is expected to expand our understanding of 
molecular mechanisms.  
 
2.1.2. Biological Sources in Cancer and Proteomics Research 
 
Proteomics technique is basically depends on identifying the protein profile 
changes by comparing total proteins of two different samples as mentioned earlier. 
These samples can be obtained from several biological sources to compare the protein 
contents efficiently. Cancer cell line, human tissue and body fluids are available as a 
biological source for studying the proteome in cancer (Chen and Yates, 2007). 
Cancer cell lines are largely in use in cancer-related proteomics researches, 
especially in vitro cancer progression studies, which present many advantages. One of 
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the positive aspects of this sample is that they are both renewable and limitless self-
replicating sources which provide large quantities of biological samples for proteomic 
technique. Another advantage is the predisposition of cancer cell line towards the gene 
manipulation. An additional benefit of them is their low cost, because they are easily 
acquired by using the cell culture. Combination of all the benefits resulted in 
tremendous amount of cell line utilized clinical research. Although there are many 
advantages of cell lines in the usage of proteomics, of course they are not without 
drawbacks. The most significant disadvantage is that the possibility of subpopulation 
formation on account of the phenotypic alterations in cell culture. 
Human tissues are another biological source which can be applied to cancer 
investigations by the method of proteomics. The evaluation of changing protein levels 
lets broaden our horizon for both disease progression and new therapeutic options. 
Actually, human tissue have the high physiological/pathological relevance as a positive 
feature, unfortunately, the study of human tissues have the higher cost as compared to 
cancer cell line and also they have limited availability.  
  One of the most studied biological samples in cancer research is body fluids, 
such as urine, saliva and plasma, since they have good advantages like low cost, easy to 
obtain from patient, high physiological and pathological relevance. However, 
characterizing the proteome of that fluid presents significant challenges due to extreme 
complexity and large dynamic range in protein concentrations compared to cell lines 
and tissues for the study of proteomics research (Lee et al., 2006). 
 
2.1.3. Exploitation of Protein Profiling in MM 
 
Because malignant plasma cells lose regulation of growth controlling 
mechanisms, in most cases signaling pathways involving numerous proteins are altered, 
as mentioned before. When this is taken into account, not surprisingly, expression 
patterns of growth-inducing and growth-suppressing genes change with malignant 
transformation (Bártek et al., 1991). Therefore, monitoring these changes is of great 
importance for understanding carcinogenesis, identifying diagnostic markers, and 
developing new therapeutics for MM. And also it is very significant for the usage of 
Bortezomib in other cancer type therapies. The most widely used methods for this 
involve examination of differential gene expression by assessing the mRNA levels in 
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the given cells. On the other hand, this methodology comes from a reductionist point of 
view, as it neglects the dynamic nature of protein translation and further modifications 
that take place beyond transcription. As such, an approach involving direct proteomic 
methods might be a better choice for obtaining more accurate insight into what is 
happening at the cellular level in MM. 
 It is clear that proteomic techniques and protein profiling are especially valuable 
for obtaining a deeper understanding of malignant transformation, improved 
diagnostics, and more accurate prognostic predictions, and for the development of 
effective therapeutic options. Genomics has provided a considerable body of useful 
information on the alterations in cancer cells by identifying the genes responsible for 
tumor suppression and growth, but as long as the complex interactions of proteins and 
the dynamic nature of protein synthesis are overlooked, genomics will be unable to 
establish a complete understanding of MM. Because the information stored in genes is 
reflected in the phenotype by proteins, assessment of proteins in the cell at a given time 
would provide accurate and detailed insight into the specifics of the myeloma cells.  
 
2.1.4. Techniques for Determining Changes in Protein Profiles 
 
Proteins are important targets for drug discovery and are utilized in cancer 
research because there are defects in the protein machinery of cells undergoing 
malignant transformation. Identification of protein profiles is clinically promising in the 
development of potential new drugs or treatment options to eradicate various 
malignancies, including, but not limited to, those of hematologic origin. Changes in 
protein profiles provide a wide variety of critical data. By examining these alterations, 
proteins that have a profound impact on the progression of diseases can be identified, 
making the development of individually tailored drugs possible (Twyman, 2004). 
Because of its importance, recent technologic advances have opened a new era for 
analyzing changes in protein profiles. To date, many of the high-throughput protein 
identification and characterization methods developed for proteomics have been applied 
to protein profiling. Among them, the most widely and efficiently used ones are Two 
Dimensional Poly Acrylamide Gel Electrophoresis (2D PAGE) and Matrix-Assisted 
Laser Desorption Ionization Time of Flight (MALDI TOF) Mass spectrometry. 
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2.1.4.1. Gel Electrophoresis  
 
Electrophoresis is a bio-analytical method utilized for the isolation of 
biomolecules depending on the mobility of charged molecules under the influence of an 
electric field. When an electric field is applied, any charged molecule in solution will 
migrate. (Twyman, 2004). Mobility of a molecule is based upon the magnitude of its 
charge, molecular weight, and structure. Many biopolymers, such as proteins are 
charged either by coating with the anionic detergent sodium dodecylsulfate (SDS) or by 
acid-base association-dissociation reactions of amine and carboxylic acid parts of them, 
so they can also be separated by electrophoretic methods (Mikkelsen and Corton 2004). 
Electrophoresis, which is the central component of the proteomic research, is 
commonly carried out in a gel that is formed by the polymerization of acrylamide, so it 
is called polyacrylamide gel electrophoresis. The reaction mechanism that results in a 
gel with a characteristic porosity which depends on the polymerization conditions and 
monomer concentrations can be seen in Figure 2.3 (Kinter and Sherman 2000).  
 
 
Figure 2.3. Reaction of polyacrylamide gel formation 
(Source: Gallagher, 2008) 
 
In the presence of an initiator generally ammonium persulfate and a catalyst 
commonly tetramethylethylenediamine [TEMED, (CH3)2N(CH2)2N(CH3)2], 
polyacrylamide gels are prepared by the copolymerization of acrylamide monomer with 
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bis-acrylamide (N,N'-methylene-bisacrylamide). Polymerization is initiated by 
ammonium persulfate and TEMED.  
The degree of cross-linking is very important in the formation of polyacrylamide 
gel. Because, the lower degrees of cross-linking gel allows to pass larger protein 
transition. 
 
2.1.4.1.1. One-Dimensional Gel Electrophoresis (1D PAGE) 
 
One-dimensional gel electrophoresis (1D-GE or SDS-PAGE) is the most 
commonly used protein seperation technique in proteomic studies. This method 
basically depends on separating proteins according to their molecular weight (size) 
difference. Most commonly, the strong anionic detergent SDS is used in combination 
with a reducing agent (mercaptoethanol or DTT) to surround the proteins 
homogeneously to dissociate them. The denatured polypeptides (simple rod-like shape 
of the proteins) gain a negative charge in constant proportion to molecular weight by 
binding SDS. By this way, the newly formed complex starts to migrate through the 
pores of the polyacrylamide gel towards the positive electrode, when the gel expose to 
high voltage. As compared to larger ones, smaller proteins migrate further through the 
gel, depending on their molecular weight (Liebler, 2002). 
 
2.1.4.1.2. Two-Dimensional Gel Electrophoresis (2D PAGE) 
 
SDS-PAGE has been utilized for several decades for the protein separation. The 
method is delicate to separate only 80-100 different protein components where cell 
proteomes are intensely complex holding several thousand of proteins. So, it is not 
sufficient for some comprehensive protein studies. Two-dimensional gel electrophoresis 
(2D-GE or 2D PAGE) firstly introduced by O’Farrell in 1975 (O’Farrell 1975). 2D 
PAGE can separate thousands of proteins simultaneously. Additionally, it can be also 
used to determine the protein alterations given a stress condition. Because of these 
reasons, it is is still the most accepted protein separation method in proteomics studies. 
Every single spot formed in 2D PAGE analysis demonstrates an individual protein 
species and its specific coordinates. The intensity of a spot in the gel implies the amount 
of that actual protein produced (Bendixen 2005). 
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 2D-GE separates protein mixture in accordance with two distinct properties. In 
the first dimension, proteins are separated depending on their isoelectric point (pI, is 
known the pH at which a protein has no net charge) disparity, whereas in the second 
dimension, the system uses the molecular weight difference. It means that proteins are 
resolved according to their molecular weight. Isoelectric focusing (IEF) is coupling with 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for protein 
separation, generally. 
  Recently, the importance of 2D-GE system is rapidly increasing, as it not only 
can be combine with the most biological studies but also has a capacity to separate up to 
10000 protein spots on one gel. Furthermore, it can monitorize more than 5000 proteins 
simultaneously, having nearly 2000 proteins routinely, hinging upon the pore size in 
acrylamide gels and pH gradient utilized. As compared to 1D-GE, it is more sensitive 
thanks to the properties of detection and quantification nearly 1 ng amount of protein 
per spot. 
By loading a range of protein markers whose molecular masses are already 
known in one of the line of the polyacrylamide gel, the molecular weights of the 
proteins in the sample can be estimated. 
 
 
Figure 2.4. Schematic Representation of 2D PAGE 
(Source: Nelson and Cox 2008) 
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2.1.4.2. Detection of Protein Spots and Image Analysis 
 
 The last procedure of 2D-PAGE is the visualization of protein spots on gel by 
staining methods. Detection of protein spots can be commonly achieved by six 
techniques. These are Coomassie Brillant Blue (CBB) Staining, silver staining, negative 
staining with metal cations (e.g. zinc imidazole), staining or labeling with organic or 
fluorescent dyes, detection by radioactive isotopes, and by immunological detection, 
respectively. Among these methods, CBB staining, silver staining and fluorescence 
staining are the most preferred detection methods for proteomic researches.  
There are some notable characteristics to select the most suitable staining 
technique for ideal protein detection on 2D PAGE. First of all, it should be sensitive 
(low detection limit), well-matched with mass spectrometry and reproducible. And also 
it should possess linear and wide dynamic range. However, there is no method that have 
all of these properties exactly.  
Each type of protein stain has its own characteristics and limitations with regard 
to the sensitivity of detection and the types of proteins that stain best (Table 2.1). 
 
Table 2.1. Characteristics of protein stains 
Gel Stain Sensitivitiy 
Process Time 
and Steps 
Advantages 
 
 
SYPRO Ruby  
Protein Gel Stain 
 
 
 
1 ng 
 
 
 
3 hr / 2 steps 
 Mass spectrometry 
compatible, 
 High detection sensitivity, 
 High dynamic range, 
 Reproducility, 
 Allows protein analysis in 
fluorescent imagers. 
Literature 
(Berggren et al., 2000; Nishihara and Champion, 2002; 
Lilley and Friedman, 2004). 
 
Coomassie 
Brillant 
Blue 
G-250 10 ng 2.5 hr / 3 steps  Mass spectrometry 
compatible, 
 Easily visualized, 
 Nonhazardous 
 Low cost  
R-250 40 ng 2.5hr / 2 steps 
R-350 40 ng 5 hr / 3 steps 
Literature 
(Neuhoff et al., 1988; Berggren et al., 2000; Patton, 2002; 
Mackintosh et al., 2003; Candiano et al., 2004). 
Silver Stain 1 ng 1.5hr / 3 steps 
 High detection sensitivity, 
 Low background 
Literature (Heukeshoven and Dernick, 1985; Merril et al., 1986). 
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The sensitivity that is achievable in staining is designated by: 
 
 The amount of stain that binds to the proteins, 
 The intensity of the coloration, 
 The difference in coloration between stained proteins and the residual 
background in the body of the gel (the signal-to-noise ratio). 
 
Unbound stain molecules can be washed out of the gels without removing much 
stain from the proteins. 
Subsequent to the staining procedure, in order to analyze the spot detection, 
intensity, size, and shape, background correction, gel matching, normalization, 
quantification, etc. the gel images necessitate to be turned into digital data by using a 
charge-coupled device (CCD) camera or a scanner. Following, the image obtained from 
the CCD camera is analyzed by computer based software, such as DECODON Delta2D, 
PD Quest or Image J. 
Finally, the spots are cut out from gel and digested (in-gel digestion) into 
peptide fragments with trypsin enzyme to attain the determination of protein spots 
(newly formed, lost or up- or down-regulated) in polyacrylamide gel. Next, these spots 
are identified using mass spectrometry and database searches. 
 
2.1.4.3. In-Gel Digestion 
 
 In-gel digestion is the most widely used step of sample preparation for the mass 
spectrometric analysis of proteins. Its significance is coming from the protein databases, 
because they are generated depending on the peptide masses that cause peptides 
preferable against intact proteins. In addition to this, mass spectrometry can produce 
measurement errors with the increasing length of the peptide chain. 
 The method is introduced by Rosenfeld in 1992. It can be applicable both one 
and two dimensional polyacrylamide gels (Rosenfeld et al., 1992). 
 In most of the proteomic studies, trypsin is a universal choice owing to its 
exceptive properties as a protease for sequencing experiments with tandem mass 
spectrometry (MS/MS). It cleaves amide bonds in proteins at the C-terminal side of 
lysine and arginine residues. It forms small peptides which are generally in the mass 
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range of 600-2500 Da. This is the ideal protein digestion for mass spectrometry. 
Actually, peptides having 6-20 amino acids are optimum for MS analysis and database 
searches. There are also different proteases exist and used for in-gel digestion process 
such as chymotrypsin, pepsin etc. The only difference is their cleavage characteristics. 
  
 
Figure 2.5. Schematic Representation of In-Gel Digestion  
(Source: Jiménez et al., 2001) 
 
2.1.4.4. ZipTip (C-18 Colon) 
 
Following the in-gel digestion process, peptides are required to purify to 
eliminate gel contaminants such as salts, buffers, and detergents. To obtain good 
spectra, it is essential to keep the salt concentrations in buffers to a minimum. If the gel 
contaminants do not eliminate from peptides, they can interfere with mass spectrometry 
either inducing the poor quality mass signal or masking the peptide signals (Yates, 
1998). Thus, the obtained peptide mixtures should be purified with ZipTips (Millipore). 
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2.1.4.5. Mass Spectrometry 
 
Mass Spectrometry (MS) is an analytic technique for the determination of the 
elemental composition of a molecule. Its principle basically depends on separating 
molecular ions according to their mass-to-charge ratio (m/z). The main purposes of MS 
studies are molecular mass determination, structure characterization, quantification at 
trace levels, and mixture analysis. 
 In 1897, cathode ray tube experiments carried out by Sir J.J. Thomson cause the 
rising a new field named MS (Thomson, 1897), but it came into prominence with the 
exploration of soft ionization techniques. Electrospray ionization (ESI) was introduced 
by Fenn and his co-workers (Fenn et al., 1989) and matrix-assisted laser 
desorption/ionization (MALDI) was put into the service of science by Karas and 
Hillenkamp (Karas and Hillenkamp, 1988). MS currently plays a key role in the 
identification of proteins. High sensitivity (low attomole levels), rapidity, versatility, 
and the accuracy of the method in the field of biological science enable MS the most 
attractive properties of MS most comprehensive and used analytical technique.  
Mass spectrometer is fundamentally composed of three essential parts, namely 
the ionization source, the mass analyzer, and the detector (Figure 2.6). 
 
 
Figure 2.6. Basic Components of a Mass Spectrometer, Premier Biosoft. 
 
The ionization source is the first component of the MS. In MS analysis, the first 
vital step is to turn the analyte which is neutral into gas phase ionic species to be able to 
check their motion. If the energies higher than ionization energies, fragmentation 
happens. Next, ions are accelerated towards a mass analyzer, which is the second 
component of the MS, through a voltage difference. Then, the charged fragments of the 
molecular ions are separated according to their m/z ratio. The last component of MS is 
the detector (photomultiplier, micro-channel plate, electron multiplier) which detects the 
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ions resolved by the mass analyzer and it transforms the ion beam into a signal. Each of 
these three parts of mass spectrometer is under vacuum-pump systems. This high 
vacuum (10
-4
 – 10-8 torr) is required to allow the ions move freely in space without 
colliding or interacting with other species. 
 
2.1.4.5.1. Ionization Methods 
 
Sample ionization is of great significance in mass spectrometric analysis as the 
compound is required to be charged and ionized. The conversion of neutral molecules 
into gas phase ionic species is achieved by ionization sources, so that electric and 
magnetic fields can be used to exert forces on charged particles in a vacuum-pump 
system for mass analysis. The most common techniques for ionization are matrix-
assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI) which 
are soft ionization techniques.  
The result of ionization, ion separation and detection is a mass spectrum that can 
provide structural information. 
 
2.1.4.5.1.1. Matrix-Assisted Laser Desorption/Ionization (MALDI) 
 
Matrix-assisted laser desorption/ionization mass spectrometry (MALDI) was 
first introduced by Karas and Hillenkamp in 1988 (Karas and Hillenkamp 1988) as 
mentioned above. MALDI is a method that allows for the ionization and transfer of a 
sample from a condensed phase to the gas phase. This technique has gained a wide 
acceptance for analysis of biological macromolecules with masses up to 500 kDa. 
In this approach, the sample molecules have to be co-crystallised with a high 
molar excess of an appropriate matrix, which is a low-molecular weight energy-
absorbing organic acid,  in a ratio 1:1000, respectively. The amount of matrix must be 
much more than analyet to both absorb all ot the radiation energy and prevent the 
analyte from fragmentation. 
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  The functions of the matrix are:  
 
 Absorb and accumulate the energy of the laser radiation, 
 Protect the analytes from destruction and fragmentation.  
 
      A good matrix material should be : 
 
 Adsorb strongly at the laser wavelength, 
      Chemically inert and stable in vacuum, 
      Be able to embed the analyte, 
 Pure et least 99%, 
 Promote co-desorption of the analyte upon laser irradiation as well as 
ionisation of the analyte by donating protons. 
 
3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid) (Beavis and Chait, 
1989) and α-cyano-4-hydroxycinnamic acid (CHCA) (Beavis et al., 1992) are the most 
preferred and popular matrices in proteomic researches. 
In MALDI, process begins with the sample preparation. For the preparation, 
matrix and our sample (analyte) mix in an eppendorf tube, and then this prepared 
mixture spots to the MALDI Target and allows to dry. After it is dry, the target is 
transferred in the vacuum chamber of the mass spectrometer. UV-Laser pulses are 
directed at the sample plate, which carries the co-crystallized peptides and matrix 
mixture, with a high energy (~10
6
 W/cm
2
). A large proportion of the laser beam is 
efficiently absorbed by the matrix crystals inducing evaporation of the matrix, and this 
energy is transferred to the analyte as heat in a controlled manner (it means that there is 
no fragmentation). That is the most important stage in MALDI. If there is no problem, 
analyte molecules are converted into gas-phase ions by gas phase proton-transfer 
reactions. Finally they are directed into the mass analyzer by appropriate electric fields 
(Figure 2.7).  
MALDI permits the analysis of high molecular weight compounds with high 
sensitivity. And also it has an ease of use while tolerating small amounts of 
contaminants like salts and surfactants.  
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Figure 2.7. Illustration of the principles behind MALDI  
(Source: Barker, 1999; Hoffmann and Stroobant, 2003) 
 
2.1.4.5.2. Mass Analyzers 
 
After the ions are generated by ionization sources, a mass analyzer is required to 
separate them depending on their m/z ratios. It is the most remarkable advantage of the 
mass analyzer to controll and manipulate the ion motion by applying suitable electric 
and magnetic fields. Hence, the number of ions at each individual m/z value can be 
detected. 
The the resolution, the transmission and the upper mass limit are three main 
crucial properties of an mass analyzer. The resolution identifies the capability of the 
mass analyzer to separate ions of similar m/z. The transmission is correspond to the ratio 
between the number of ions reaching the detector and the number of ions generated in 
the sources. The upper mass limit determines the measured highest value of the m/z 
ratio. Besides, mass accuracy, detection sensitivity, and scan speed also affect the 
performance of the mass analyzer. 
Several types of mass analyzers can be used in proteomics study. Time-of-flight 
(TOF), quadrupole linear, quadrupole ion trap, Fourier Transform Ion Cyclotron 
Resonance (FT-ICR) analyzers are the most known analyzers useful for biomolecules. 
All of these analyzers are quite different from each other in terms of both experimental 
design and performance parameters like resolution, transmission and the upper mass 
limit. 
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2.1.4.5.2.1. Time-of-Flight Mass Analyzer (TOF) 
 
A time-of-flight (TOF) mass analyzer was firstly introduced by Stephens in 
1946 (Stephens, 1946). It is one of the simplest instrument in terms of its working 
principle.  
Chiefly, TOF analysis is based on accelerating a set of ions to a dedector with 
the same amount of kinetic energy. All the ions are exposed to high voltage to create an 
electric field that allows the ions to be accelerated. After acceleration, the ions go to a 
field-free region where they fly at a velocity that is inversely proportional to their m/z. It 
means that, the smaller ions reach the dedector first because of their greater velocity and 
the larger ions take longer. Because the ions have the same energy, yet a different mass, 
the ions reach the dedector at different times. Thus the analyzer is called time-of-flight 
because the m/z is determine from the ions time of arrival. Finally, required time is 
measured for the travel of the ion through the length of the field-free region. 
The resolution is a very important parameter in proteomics studies. In a TOF 
mass analyzer, both the length of the flight tube and the accelerating the voltage affect 
the resolution. So, in order to improve the sensitivity and to increase the resolution, both 
acceleration voltages can be lowered and reflectron modes which increase the length of 
the flight tube can be placed at the end of the drift zone (Figure 2.8). In summary, using 
a long flight tube is the only way to have both high resolution and high sensitivity. 
 
 
Figure 2.8. Schematic Representation of Reflectron Time-of-Flight Mass Analyzer  
(Source: The University of Bristol, 2007) 
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There is no doubt that different mass analyzers can connect with different 
ionization sources. However, the harmony between mass analyzers and ionization is of 
great value. Depending on this reality, TOF analyzer is well suited to the MALDI 
(MALDI-TOF) ionization process, as the laser beam takes individual shots instead of 
working in continuous procedure. Figure 2.9 shows a MALDI-TOF Mass Spectrometer. 
Similarly, quadrupole and ion trap can coupled to ESI (Figure 2.10) (Micallef et al., 
2010). 
 
 
Figure 2.9. A MALDI-TOF Mass Spectrometer 
(Source: Liebler 2002) 
 
 
Figure 2.10. A Mass Spectrometer (Representation of the most suitable source-analyzer-
dedector combination) (Source: Micallef et al., 2010) 
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2.1.4.5.3. Detectors 
 
 Dedector is the final component of a mass spectrometer. After the ions pass 
through the analyzer, they arrive and hit the surface of the dedector and then it 
determines ion abundance for each corresponding ion resolved by the mass analyzer 
depending on their m/z value and generates a mass spectrum (Micallef et al., 2010).  
Detectors can be categorized in two class. First category of detectors are 
responsible for measuring of the charges that reach the detector directly. Second 
category of detectors play a central role to increase the intensity of signals. While 
photographic plate and the Faraday cage are comprised in the first category, 
photomultiplier, electron multiplier and microchannel detectors are included in the 
second category.  
 
2.1.4.6. Tandem Mass Spectrometry (MS/MS) 
 
The basic principle of tandem mass spectrometry (MS/MS) is to isolate the 
precursor ion in the first spectrometer and then analyze the product ions in the second 
spectrometer. The process begins with selecting an ion. Following, this ion is 
fragmented through collision (generally with Ar) and the fragments are analyzed by the 
other spectrometer. 
 
2.1.5. Advantages and Drawbacks of Protein Profiling 
 
Although analysis of important proteins in biological systems is important, there 
are several drawbacks of protein profiling due to techniques like mass spectrometry in 
combination with separation tools such as 2D PAGE (Washburn et al., 2001; Wolters et 
al., 2001; Aebersold and Mann, 2003). First of all, these techniques are labor intensive 
and time consuming for the analysis of proteins. Improved robotics may increase the 
frequency with which these techniques are utilized, as well as their efficiency. 
Secondly, 2D PAGE lacks the sensitivity to detect low quantities of proteins and 
therefore requires a significant quantity of biological material (Sydor and  Nock, 2003; 
Issaq and Veenstra, 2008). Additionally, most of the time high-quantity proteins can 
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mask low-quantity proteins that may be important biomarkers for the disease studied. 
To overcome this type of drawback immunodepletion and multidimensional 
chromatography may be a reasonable solution (Cho et al., 2005). Through sample 
purification, low-quantity proteins may be lost due to interactions with other high-
quantity proteins; therefore, all steps of purification must be analyzed. Sample 
collection, processing, and, ultimately, sample measurement are also very crucial for the 
utilization of protein profiling in many clinical settings. Consistency, use of strict 
protocols, running replicates for each sample, and increasing the sample count can be a 
general solution to eliminating such drawbacks. Other obstacles to the use of techniques 
in protein profiling can be ascribed to poor resolution of spots after 2D PAGE, non-
identification of mass spectrometry peaks, and the limitations of databanks for unknown 
proteins. The advantages and disadvantages of the techniques used for protein profiling 
are summarized in Table 2.2. 
 
Table 2.2. Advantages and disadvantages of protein profiling techniques 
(Source: Twyman, 2004; Mohamed et al., 2011) 
 
Techniques Advantages Disadvantages 
Usage of Cell Lines 
and 
Protein Extraction 
from Cells 
 Renewable,  
 Limitless self-replicating, 
 Predisposition towards gene 
manipulation, 
 Low cost. 
 Subpopulation formation, 
 Sample contamination, 
 Protein degradation, 
 Extraction of membrane 
proteins. 
 
 
Two Dimensional  
Gel 
Electrophoresis 
(2D PAGE) 
 
 High resolution,  
 Quantitative,  
 Qualitative,  
 Sample variety (cell lines 
and body fluids),  
 Many protein analyses in a 
single run. 
 Slow, 
 Lacks automation, 
 Poor reproducibility, 
 Labor intensive, 
 Tedious procedure, 
 Requires a significant 
quantity of sample, 
 Lacks sensitivity for low-
quantity proteins. 
 
 
MALDI-TOF Mass 
Spectrometry 
 Fast,  
 Buffer / salt tolerance, 
 Off-line,  
 Mass accuracy, 
 Mixture of samples okay, 
  Small and large 
polypeptide analysis. 
 
 Limited databank 
information, 
 Limited resolution of 
peaks, 
 Low dynamic range of 
detection. 
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2.1.6. Aim of the Study 
 
Investigating protein profiles and understanding the dynamic alterations of 
cellular proteins are of great importance for diagnostic and therapeutic purposes in 
clinical settings. This is because most diseases, cancers in particular, are reflected as 
driven by protein alterations in cells. As such, proteomic methods enhance our 
understanding of the characteristics of various cancers via, making it possible to 
discriminate healthy and malignant cells more accurately, development of novel 
therapeutics that target altered protein signaling pathways, and assessment of what 
changes occur at the protein level in cells in response to treatment with drugs, leading to 
the evaluation of therapeutic efficacy. 
In the light of this valuable knowledge, the objective of this project was mainly 
to both determine the cytotoxic and apoptotic effects of Bortezomib on Multiple 
Myeloma U-266 cells and find out the changes in protein profiles of MM U-266 cells 
when they exposed to Bortezomib, by proteomics studies.  
The cytotoxic effects were determined by measuring the IC-50 value using XTT 
cell proliferation assay and apoptotic effects were assessed measuring the changes in 
caspase-3 enzyme activity and loss of mitochondrial membrane potential (MMP). After 
assigning the MM U-266 cells as a control while, Bortezomib applied MM U-266 cells 
as a Bortezomib, protein isolation was carried out from these two compartments 
separately. Following to the extraction of total protein content, a comparison of protein 
profiles in these two different states was carried out using two-dimensional 
polyacrylamide gel electrophoresis (2D-PAGE). Differentially expressed protein spots 
(increased and/or decreased or appear and/or disappear) were in-gel digested and 
identified by MALDI-TOF-TOF Mass Spectrometry, and database searches were 
performed (Mascot search engine and NCBInr protein database) in order to discover the 
differences in details between Bortezomib applied and control group MM U-266 cells at 
the level of proteins. The functions of Bortezomib related proteins were also discussed. 
Proteomic study provides an excellent opportunity to find the differentiated 
proteins depending on Bortezomib effect. For future perspectives, these differentiated 
proteins can let to be possible to treat other cancer types by same anti-cancer agent. 
Additionally, the data obtained by this study can be helpful for medical schools and 
drug designers and may also provide new treatments.  
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CHAPTER 3 
 
MATERIALS AND METHODS 
 
3.1. Materials 
 
3.1.1. Medias 
 
Medias were listed in Appendix A. 
 
3.1.2. Chemicals, Reagents and Solutions 
 
Reagents and solutions were presented in Appendix B. 
 
3.2. Methods 
 
3.2.1. Cell Lines and Culture Conditions 
 
U-266 human MM cells were kindly obtained from the German Collection of 
Microorganisms and Cell Cultures (Germany). The cells were grown and maintained in 
RPMI-1640 growth medium containing 10% fetal bovine serum (FBS) and 1% 
penicillin-streptomycin (Invitrogen) at 37°C in 5% CO2. Medium was refreshed every 3 
days. In order to passage the cells, whole cell suspension was taken from tissue culture 
flask (75cm
2
) into a sterile falcon tube (50ml) and then centrifuged at 1000 rpm (~800g) 
for 10 minutes (min) at room temperature. After centrifugation, the supernatant was 
removed and the pellet was washed with 3-4 mL Phosphate Buffered Saline (PBS) and 
centrifugation process was repeated. In the following step, supernatant was removed 
from the tube and the pellet was resuspended with 15 mL of RPMI-1640 (10% FBS and 
1% Penicillin-Streptomycin). Then, it was transferred into a sterile 75cm
2
 filtered tissue 
culture flask and incubated in CO2 incubator.  
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3.2.2. Thawing the Frozen Cells 
 
Cells (1ml) were removed from frozen storage at -196°C (Liquid Nitrogen) and 
quickly thawed in a water bath at 37°C so as to acquire the highest percentage of viable 
cells. When the ice crystals melted, the content was immediately transferred into a 
sterile filtered tissue culture flask (25cm
2
) containing 5-6 ml of RPMI-1640 growth 
medium and incubated overnight at 37°C in 5% CO2. After incubation, cells were 
passaged as mentioned before.   
 
3.2.3. Freeze the Cells 
 
Cells taken from tissue culture flask were centrifuged at 1000 rpm for 10 
minutes at room temperature. After centrifugation, the supernatant was carefully 
removed and the pellet was resuspended by the addition of 4.5ml FBS and 0.5ml 
dimethyl sulfoxide (DMSO). Then, gentle pipetting was applied and the cell suspension 
was transferred to the cryogenic vials (1 ml) by labeling. At the following step, these 
cryogenic vials were lifted to freezing compartment -80°C, for overnight by wrapping in 
cotton wool in a polystyrene box to prevent the cells from shock. Finally, they were 
transferred to liquid nitrogen dewar for long-term storage. 
 
3.2.4. Cell Viability Assay 
 
The assay primarily based on distinguishing dead cells from alive cells with the 
addition of trypan blue dye. ~30 µl of trypan blue dye was mixed ~30 µl of cells (1:1 
ratio, volume/volume) in order to measure the viability of cells. When cells were treated 
with trypan blue dye, viable cells would be normally impermeable to it, whereas dead 
cells would permeate by virtue of breakdown in membrane integrity. Thus, cells can be 
observed as unstained cells that are alive or blue stained cells that are dead under a 
microscope. By applying this assay, cells were counted using a hemocytometer in the 
presence of trypan blue solution, under microscope. Then the percentage of viable cells 
was calculated. Cell viability assay was conducted before each experiment.  
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3.2.5. Cell Proliferation Assay 
 
Anti-proliferative effects of Bortezomib on U-266 MM cells were determined by 
XTT cell proliferation assay. The principle of this assay is based on the ability of 
metabolic active cells to reduce the tetrazolium salt XTT to orange colored compounds 
of formazan by their mitochondrial enzyme. These formazan molecules formed is water 
soluble and can be measurable at the wavelength of 492 nm with a spectrophotometer. 
Briefly, the test procedure includes cultivation of cells in a 96-well plate, adding 
the XTT reagent (The procedure for preparation of XTT Reaction Solution that was 
used in XTT Assay was given in Appendix B) and incubation for 72 hours. During 
incubation an orange color is formed. The greater the number of the active cells in the 
well, the greater the activity of mitochondria enzymes and the higher the concentration 
of the formazan compounds (dye) formed, which can then be measured and quantitated 
with a spectrophotometer. 
2x10
4
 U-266 cells (100 µl) were seeded into 96-well plates containing 200 µl 
growth medium in the absence or presence of increasing concentrations of Bortezomib 
(Figure 3.1) 
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96 Well Plate A 
Figure 3.1. The Dosage of Bortezomib (nM) Applied on MM U-266 Cells 
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96 Well Plate B 
Figure 3.1. The Dosage of Bortezomib (nM) Applied on MM U-266 Cells (cont.) 
 
In Figure 3.1 ; 
 
 C is correspond to control group (100 µl (2x104)  
MM U-266 Cells + 100 µl RPMI-1640 Growth Medium), 
 0.1 is correspond to 0.1 nM Bortezomib concentration (100 µl (2x104) 
MM U-266 Cells + 100 µl 0.1 nM Bortezomib), 
 1 is correspond to 1 nM Bortezomib concentration (100 µl (2x104)   
MM U-266 Cells + 100 µl 1 nM Bortezomib), 
 5 is correspond to 5 nM Bortezomib concentration (100 µl (2x104)   
MM U-266 Cells + 100 µl 5 nM Bortezomib), 
 10 is correspond to 10 nM Bortezomib concentration (100 µl (2x104) 
MM U-266 Cells + 100 µl 10 nM Bortezomib), 
 20 is correspond to 20 nM Bortezomib concentration (100 µl (2x104) 
MM U-266 Cells + 100 µl 20 nM Bortezomib), 
 50 is correspond to 50 nM Bortezomib concentration (100 µl (2x104) 
MM U-266 Cells + 100 µl 50 nM Bortezomib), 
 70 is correspond to 70 nM Bortezomib concentration (100 µl (2x104) 
MM U-266 Cells + 100 µl 70 nM Bortezomib), 
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After 72 hour incubation period at 37°C in 5% CO2, they were treated with 50 µl 
XTT reagent for 4 hours at CO2 incubator. After that, the absorbances of the samples 
were read under 492 nm wavelength of light by Elisa reader (Thermo Electron 
Corporation Multiskan Spectrum, Finland) and graphed cell proliferation plots. Finally, 
IC50 value (the concentration of drug that inhibits 50% of cell proliferation as 
compared to untreated control) of Bortezomib was calculated from cell proliferation 
plots. 
 
3.2.6. Evaluation of Apoptosis 
 
3.2.6.1. Measurements of Caspase-3 Enzyme Activity 
 
Also called programmed cell death or cell suicide, apoptosis is an integral and 
necessary part of life cycle of organisms. In the human body, about a hundred thousand 
cells are produced every second by mitosis and a similar number of them die by 
apoptosis (Vaux and Korsmeyer, 1999). The apoptotic mode of cell death can be 
described as a process which plays an important role in the improvement and 
homeostasis of multicellular organism and in the regulation and maintenance of the cell 
populations in tissues upon pathological and physiological conditions (Jacobson et al., 
1997; Meier et al., 2000; Hengartner, 2000; Leist and Jaattela, 2001). Apoptosis can be 
triggered by various stimuli from outside or inside the cell. For example, ligation of cell 
surface receptors, DNA damage as a cause of defects in DNA repair mechanisms, 
treatment with cytotoxic drugs or irradiation, a lack of survival signals, contradictory 
cell cycle signaling or developmental death signals (Gewies, 2003). It is doubtless that 
apoptotic processes are of widespread biological and biochemical significance. A major 
biochemical feature of apoptosis is the sequential activation of the caspases (cysteine-
dependent aspartate- specific proteases), a family of proteases whose substrate include 
large protein precursors of enzymes capable of destroying DNA (endonucleases); lamin 
and actin (proteases); and proteins involved in DNA repairing, RNA splicing, signal 
transduction and transcription factors (Thornberry and Lazebnik, 1998; Hengartner, 
2000; Green 2000; King and Robins, 2006).  
One of the vital members of these caspases family is Caspase-3 enzyme which is 
the key component in that it takes part in the center of apoptotic pathways (Bratton et 
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al., 2000). This enzyme is also responsible for the cleavage of important cellular 
substrates resulting in the classical biochemical and morphological changes associated 
with the apoptotic phenotype. The afore-cited enzyme is activated either in response to 
the ligation of cell surface death receptors (extrinsic apoptosis pathways) or in response 
to signals originating from inside the cell (intrinsic apoptosis pathways) (Figure 3.2) 
(MacFarlane and Williams, 2004). 
 
 
Figure 3.2. Apoptosis: The Extrinsic and Intrinsic Pathways 
(Source: MacFarlane and Williams, 2004) 
 
Apoptotic stimuli (cell injury, the release of certain steroids and growth factor 
withdrawal) trigger the release of apoptogenic factors such as cytochrome c (Gewies, 
2003). Cytchrome c is an essential protein component of the mitochondrial electron 
transport chain that is a loosely bound to the outside of the inner mitochondrial 
membrane (Lieberman and Marks, 2009). The intrinsic apoptosis pathway initiates with 
the release of it from the inter-mitochondrial membrane space to the cytosol. Once 
released, cytochrome c binds to Apoptotic Protease-Activating Factor-1 (APAF-1) and 
procaspase-9 which bring about formation of the Apaf1–caspase-9 active complex 
called apoptosome and activation of the initiator caspase-9 (Denault and Salvesen, 
2002). Then caspase-3 enzyme is activated by the activate caspase-9 (Salvesen and 
Renatus, 2002b; Adams, 2003; Danial and Korsmeyer, 2004). 
Other apoptosis pathway (extrinsic) activated via death receptor activation by a 
ligand (usually a cell surface protein on another cell). Triggering of cell surface death 
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receptors of the Tumor Necrosis Factor (TNF) results in rapid activation of the initiator 
caspase-8 making a scaffold after its recruitment to a trimerized receptor-ligand 
complex (DISC) through the adaptor molecule Fas-Associated Death Domain Protein 
(FADD) (Sartorius et al., 2001). Then activated caspase-8 cleaves and thereby activates 
caspase-3 for the execution of apoptosis (Gewies, 2003). 
Changes in caspase-3 enzyme activity of MM U-266 cells in response to 
Bortezomib were evaluated by using caspase-3 colorimetric assay kit (R&D Systems, 
USA) as described previously (Baran et al., 2007). This assay is based on 
spectrophotometric detection of the chromophor p-nitroanilide (pNA) after cleavage 
from the labeled substrate DEVD- pNA . The pNA light emission can be quantified at 
405 nm. 
In short, 1x10
6 
cells were seeded in a 6-well plate in 2 ml growth medium in the 
absence or presence of increasing concentrations of Bortezomib (1 nM, 10 nM, 20 nM) 
at 37°C in 5% CO2 for 72 hours. Untreated cells were used as control group.  
 
   
   
 
Figure 3.3. Aplied Bortezomib Doses on U-266 Cells for Caspase-3 Enzyme Activity 
 
In Figure 3.3 ; 
 
 C is correspond to control group (1x106 U-266 Cells / 2 ml / well), 
 1 nM is correspond to 1 nM Bortezomib concentration (1x106 U-266 
Cells / 2 ml / well + 1 nM Bortezomib in 2 ml), 
 10 nM is correspond to 10 nM Bortezomib concentration (1x106 U-266 
Cells / 2 ml / well + 10 nM Bortezomib in 2 ml), 
C 
 
20 nM 
10 nM 1 nM 
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 20 nM is correspond to 20 nM Bortezomib concentration (1x106 U-266 
Cells / 2 ml / well + 20 nM Bortezomib in 2 ml), 
 
After incubation, the cells were taken to a falcon tube and centrifugated at 1000 
rpm for 10 minutes. Then, the supernatant was gently removed and discarded, while the 
cell pellet was lysed by adding 50 µl of chilled Cell Lysis Buffer (1X) to get cell lysate. 
Then, the cell lysate was incubated on ice for 10 minutes before centrifugation at 
10000g (~14000 rpm) for 1 minute. Next, the supernatants were transferred to new 
microcentrifuge tubes. So as to measure caspase-3 enzyme activity, reaction mixture 
was prepared in 96-well plates with the addition of 50 µl of Reaction Buffer (2X) 
(containing 10 mM DTT), 50 µl of sample and 5 µl of caspase-3 colorimetric substrate 
(DEVD-pNA) and incubated for 2 hours at 37°C in 5% CO2. After that, absorbance of 
the sample was read under 405 nm wavelengths by Elisa reader (Thermo Electron 
Corporation Multiskan Spectrum, Finland). 
 
3.2.6.2. Bradford Protein Assay for Protein Determination 
 
Protein concentrations were measured by Bradford assay by using bovine serum 
albumin (BSA) as the standart. The Bradford protein assay is one of the spectroscopic 
analytical methods that are utilized to find out the total protein concentration of a 
sample (Bradford 1976). The method is also known as colorimetric assay because the 
addition of the sample causes color changes from brown that is cationic form to blue 
which is anionic form. Moreover the color of the sample becomes darker and the 
measured absorbance rises with the protein concentration increases. Basic principle of 
this method is absorption shift from 470 nm to 595 nm. When Coomassie Brilliant Blue 
G-250 (CBB G-250) dye binds to proteins through Van der Waals forces and 
hydrophobic interactions from its sulfonic groups, absorption occurs. In general, 
binding of dye to proteins becomes lysine, arginine and histidine residues, it also can 
bind tyrosine, tryptophan and phenylalanine weakly.           
Caspase-3 activity levels were normalized to protein concentrations determined 
by Bradford protein assay. A series of standard protein solutions were prepared via 
serial dilution using BSA (Bovine Serum Albumine) diluted with 1X PBS (Phosphate 
Buffered Saline) (Table 3.1). 
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The preparation of stock BSA Standard was given in Appendix B. 
 
Table 3.1. Preparation of BSA Standards and Test Sample for the Bradford Protein 
Assay 
 
S
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l 
 D
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u
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o
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Test Sample BSA Standards 
Volume, µl 
PBS 
Volume, µl 
Blank - 10 
50 µg/µl 200 200 
40 µg/µl 160 40 
20 µg/µl 100 100 
16 µg/µl 80 20 
8 µg/µl 50 50 
4 µg/µl 50 50 
2 µg/µl 50                  50 
1 µg/µl 50 50 
 
After the preparation of standard protein (BSA), protein samples were diluted 
by the ratios 1:100, 1:250, 1:500 and 1:1000) (Table 3.2).  
 
Table 3.2. Dilution of Protein Sample 
 
 
C 
1/100 10 µl Sample from C + 90 µl PBS 
1/250 20 µl Sample from C + 480 µl PBS 
1/500 20 µl Sample from C + 980 µl PBS 
1/1000 10 µl Sample from C + 990 µl PBS 
 
 
1 nM 
1/100 10 µl Sample from 1 nM + 90 µl PBS 
1/250 20 µl Sample from 1 nM + 480 µl PBS 
1/500 20 µl Sample from 1 nM + 980 µl PBS 
1/1000 10 µl Sample from 1 nM + 990 µl PBS 
 
 
10 nM 
1/100 10 µl Sample from 10 nM + 90 µl PBS 
1/250 20 µl Sample from 10 nM + 480 µl PBS 
1/500 20 µl Sample from 10 nM + 980 µl PBS 
1/1000 10 µl Sample from 10 nM + 990 µl PBS 
 
 
20 nM 
1/100 10 µl Sample from 20 nM + 90 µl PBS 
1/250 20 µl Sample from 20 nM + 480 µl PBS 
1/500 20 µl Sample from 20 nM + 980 µl PBS 
1/1000 10 µl Sample from 20 nM + 990 µl PBS 
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Next, 90 μl of Bradford reagent, which is composed of 5 mg CBB G-250, 2.5 ml 
Absolut Ethanol and 5 ml Phosphoric Acid, were seeded in a 96-well plate (Figure 3.4), 
containing 10 μl of each sample. For Blank, we used 90 μl of Bradford reagent + 10 μl 
PBS. After that, the mixture in 96-well plates was allowed to incubate at room 
temperature for 10 minutes. Finally, the absorbance of dye within the plates was 
measured at 595 nm by Elisa reader (Thermo Electron Corporation Multiskan 
Spectrum, Finland) and the standard curve was constructed by plotting the reading of 
absorbance versus μg of protein in BSA standard samples. According to the equation  (y 
= mx+n), the best straight line was acquired. In this equation ; x, which is correspond to 
protein concentration can be found  with the help of y, which is the absorbance value 
read at 595 nm. Dilution of the sample is required for absorbance to fall within the 
linear range of the grafics.    
 
 
Figure 3.4. Bradford Assay 
 
 
Blank Blank Blank 50 µg/µl 50 µg/µl 50 µg/µl 1/1000 
(1 nM) 
1/250 
(10 nM) 
1 µg/µl 1 µg/µl 1 µg/µl 1/100 
(C) 
1/100 
(C) 
1/100 
(C) 
1/1000 
(1 nM) 
1/250 
(10 nM) 
2 µg/µl 2 µg/µl 2 µg/µl 1/250 
(C) 
1/250 
(C) 
1/250 
(C) 
1/1000 
(1 nM) 
1/250 
(10 nM) 
4 µg/µl 4 µg/µl 4 µg/µl 1/500 
(C) 
1/500 
(C) 
1/500 
(C) 
  
8 µg/µl 8 µg/µl 8 µg/µl 1/1000 
(C) 
1/1000 
(C) 
1/1000 
(C) 
  
16 
µg/µl 
16 
µg/µl 
16 
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(1nM) 
1/100 
(1nM) 
1/100 
(1nM) 
1/100 
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20 
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20 
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1/250 
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(1nM) 
1/250           
(1nM) 
1/100 
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40 
µg/µl 
40 
µg/µl 
40 
µg/µl 
1/500 
(1nM) 
1/500 
(1nM) 
1/500 
(1nM) 
1/100 
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1/500 
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1/1000 
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1/1000                                                                                
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1/1000
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1/1000 
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1/1000
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1/1000 
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1/100 
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1/100 
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1/100 
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1/250 (20 
nM) 
1/250 
(20 nM) 
1/250 
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1/500 
(20 nM) 
1/500 
(20 nM) 
1/500 
(20 nM) 
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3.2.6.3.  Detection of the Loss of Mitochondrial Membrane Potential     
               (MMP) 
 
Mitochondrion is responsible for mediating the release of cytochrome-c 
molecules. Thus, it has a vital function in the induction of intrinsic apoptosis. Loss of 
mitochondrial membrane potential (MMP), that is a hallmark for apoptosis, causes to 
form pores and these pores allows to release of cytochrome-c into the cytoplasm. This 
event known as the beginning of the apoptotic response. The decrease of MMP in MM 
U-266 cells was assessed by APO LOGIX JC-1 MMP Detection Kit (Cell Technology, 
USA). JC-1, which is a signal molecule to detected the changes in MMP, is a unique 
cationic dye. In non-apoptotic cells, JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine iodide) exist as a monomer in the cytosol (green) 
and also accumulates as aggregates in the mitochondria which stain red. Whereas, in 
apoptotic cells or unhealthy cells, JC-1 exist in monomeric form and stains the cytosol 
to green. For this reason, apoptotic cells, showing only green fluorescence, are easily 
differentiated from healthy cells that show intense red fluorescence. This is the basic 
principle of the method. 
Shortly, 1x10
6 
cells were seeded in a 6-well plate in 2 ml growth medium in the 
absence or presence of increasing concentrations of Bortezomib (1 nM, 10 nM, 20 nM) 
at 37°C in 5% CO2 for 72 hours. Untreated cells were used as control group. 
 
   
   
 
Figure 3.5. Aplied Bortezomib Doses on U-266 Cells for Dedection of  Loss of MMP 
 
 
 
 
C 
 
20 nM 
10 nM 1 nM 
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In Figure 3.5 ; 
 
 C is correspond to control group (1x106 U-266 Cells / 2 ml / well), 
 1 nM is correspond to 1 nM Bortezomib concentration (1x106        
U-266 Cells / 2 ml / well + 1 nM Bortezomib in 2 ml), 
 10 nM is correspond to 10 nM Bortezomib concentration (1x106  
U-266 Cells / 2 ml / well + 10 nM Bortezomib in 2 ml), 
 20 nM is correspond to 20 nM Bortezomib concentration (1x106  
U-266 Cells / 2 ml / well + 20 nM Bortezomib in 2 ml), 
 
After this period, all samples (control group and the cells induced to undergo 
apoptosis) are taken to the falcon tubes respectively and washed with 1X PBS before 
the centrifugation at 1000 rpm for 10 minutes. Supernatants were carefully removed 
from the pellet and discarded. Then the pellets were dissolved in 500 μl of JC-1 dye and 
the cells were incubated at 37˚C in 5% CO2 for 15-30 minutes. Next, the mixtures were 
centrifuged at 400g (~1000 rpm) for 5 minutes and supernatants were carefully removed 
again. Subsequently, 2 ml of 1X Assay Buffer was added onto the pellets and vortexed 
till to be sure that it was homojenized. Immediately afterwards centrifugation was 
repeated with the same conditions (400g (~1000 rpm) for 5 minutes) to remove the 
excess dye. All the pellets were resuspended with 500 μl 1X Assay Buffer and 150 μl 
from each of them was seeded into black 96-well plate as triplicate. While the aggregate 
red form of the dye has absorption/emission maxima of 585/590 nm, the monomeric 
green form of the dye released to the cytoplasm because of the loss of MMP has 
absorption/emission maxima of 510/527 nm. The plate was read in these wavelengths 
by fluorescence Elisa reader (Thermo Varioskan Spectrum, Finland). Finally, green/red 
(510/585) values were calculated to determine the changes in MMP. 
 
3.2.7. Total Protein Extraction from MM U-266 Cells 
 
So as to extract the total proteins belonging to MM U-266 cells and 17 nM 
(which is the IC-50 value of Bortezomib on U-266 cells) Bortezomib applied U-266 
cells, whole cell suspension was taken from tissue culture flask into a sterile falcon tube 
and then centrifuged at 1000 rpm for 10 minutes at room temperature, separately. After 
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centrifugation, the supernatant was removed and the pellet resuspended in 50 μl of 
chilled Cell Lysis Buffer (containing Sodium Chloride, Potassium Chloride, Sodium 
Phosphate Dibasic, Potassium Phosphate Monobasic,Triton X100 and Water) before 
incubated on ice for 10 minutes. Following the addition of Cell Lysis Buffer, samples 
taken to microcentrifugation tube from falcon and centrifugation was performed at 
maximum speed 14.000 rpm (~10.000g) for 1 minutes at 4˚C. Supernatant, which is the 
total protein of our samples, transferred to a fresh tube and used for further studies (2D-
PAGE). 
 
3.2.8. Determination of Protein Concentration 
 
Protein concentrations of the samples were determined by using Bradford 
method as described above.  
 
3.2.9. 2D-PAGE Analysis 
 
3.2.9.1. Isoelectric Focusing (IEF) 
 
Day One 
 
The first dimension step of 2D PAGE (isoelectric focusing, (IEF)) was 
performed on 17 cm-immobiline strips which provided a linear gradient from pH 3 to 
10 (Bio-Rad) by a PROTEAN IEF Cell (Bio-Rad). 
Firstly, strips were taken out from -20°C freezer and waited in the room 
temperature till rehydration buffer is prepared (preparation of the buffer was given in 
Appendix B). Before the experiment, IEF rehydration tray was cleaned and dried. The 
passive rehydration was choosen for the rehydration step. 
Table 3.3 indicates the amount of recommended protein sample to load per IPG 
strip. 
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Table 3.3. Required Protein Sample with Rehydration Buffer 
Strip Length 17 cm (pH 3 - 10) 
Sample Volume 300 - 600 µl 
Protein Loaded 405 µg 
 
 It is also suggested that the rehydration buffer should be equal or more 
than 300 µl.  
 
Bradford results belonging to Bortezomib and control group are represented in 
Table 3.4.  
 
Table 3.4. Bradford results for protein samples 
Sample Name Protein Concentration 
Bortezomib (17 nM) 10.20 µg / µl 
Control 10.36 µg / µl 
 
 By taking notice of the recommended value in Table 3.3 and the concentration 
of two protein samples (Bortezomib and control group) in Table 3.4, protein samples 
were reconstituted with rehydration buffer. The reorganized sample values can be seen 
in Table 3.5. 
 
Table 3.5. Reconstituted sample values 
Sample 
Name 
Sample Volume Protein 
Loaded 
Bortezomib 
(17 nM) 
 
40 µl + 360 µl Rehydration Buffer = 400 µl 
 
408 µg  
Control 40 µl + 360 µl Rehydration Buffer = 400 µl 414.4 µg 
 
 According to reorganized sample values, proteins were pipetted along the whole 
length of the rehydration tray channel except for about 1 cm at each end. For this 
process it was taken care not to introduce any bubbles that might interfere with the even 
distribution of protein samples in the strip. Channels of the rehydration tray was 
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selected symmetrically to load the protein samples. It is important for us to avoid 
confusing the samples. At the same time, during the IEF step, the weigh of the tray lid is 
evenly distributed over all the samples so contact between the IPGs and the electrode 
remains uniform. After all the protein samples loaded into the rehydration tray, the 
coversheet of the strips were peeled by using forceps. Then the strips gel side down 
were gently located onto the samples, respectively. And the tray was waited for an hour 
at the room temperature to allow to strip for soaking the sample. After that each of the 
strips were overlayed with 2 - 3 ml of mineral oil so as to hamper evaporation during 
the rehydration process. It was added slowly, by carefully dripping the oil onto the 
plastic backing of the strips while moving the pipet along the length of the strip. The 
final step of the day 1, the tray was covered with a plastic lid and lifted an incubator 
(20°C) to allow to rehydrate the IPG strips.  
 
Day Two 
 
 In second day, the IEF focusing tray that has electrodes was cleaned and dried 
carefully. After that, paper wicks were placed at both ends of channels on the wire 
electrodes using forceps. It is crucial to prevent direct contact between IPG strips and 
wire electrodes, because it might cause to undesired burns on strips. Following, paper 
wicks were wetted with 8 μl of ultrapure water in order to enable electrical conductivity. 
Then, strips were taken from the rehydration tray by removing the cover and by the help 
of forceps; strips were held vertically for about 5 – 10 seconds to let the mineral oil to 
drain, carefully. Then they were transferred to related channels in the focusing tray by 
maintaining the gel side down position. Each IPG strips were covered with 2 – 3 ml of 
fresh mineral oil again and the lid was placed onto the focusing tray (positive to the left 
when the inclined portion of the tray is on the right). At the final step of isoelectric 
focusing, the focusing tray was put into the PROTEAN IEF cell and the cover of the 
tray was closed. Isoelectric focusing was performed at room temperature (~20°C) in 
three steps depending on the values in Table 3.6. 
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Table 3.6. PROTEAN IEF Cell Program 
17 cm Voltage Time Ramp Conditions 
Step 1 500 V 1 hour Linear   
 20 °C 
 50 μA / Strip 
 No Rehydration 
Step 2 1000 V 1 hour Linear 
Step 3 8000 V 8 hour Rapid 
Total 64000 Volt - hour  
 
 After the IEF run was complete, IPG strips were removed from IEF focusing 
tray and taken in a new and clean rehydration tray with the gel side up position. Before 
transferring the IPG strips, they were allowed to drain of mineral oil by holding 
vertically for 5 – 10 seconds. After they were either placed at -80ºC or immediately 
equilibrated with equilibration buffers for second dimension of the experiment.    
 
3.2.9.2. SDS-PAGE 
 
For second dimension of the experiment, Equilibration I and Equilibration II 
buffers were prepared (preparation of these two buffers were told in Appendix B). The 
strips taken from the focusing tray were equilibrated in equilibration buffers that contain 
SDS which is of great significance to transform the focused proteins taken part in the 
IPG strips into SDS-protein complexes. These complexes had unfolded structures and 
carried only negative charges. Basically, Equilibration Buffer I has DTT, which is 
necessary as a reducing agent for cleavage of sulfhydryl bonds between cysteine 
residues within a protein, Tris-HCl pH 8.8, glycerol and urea, in addition to SDS, while 
instead of DTT, Equilibration Buffer II has iodoacetamide which is used as an 
alkylation for reduced sulfhydryl groups in the protein. 
 Because SDS PAGE would carry out in the third day, the preparations began in 
second day. Related to, SDS-polyacrylamide gel was prepared. It contains only the 
separating gel but not the stacking gel. Instead of stacking gel overlay agarose was used 
to cover the strip completely. The composition of acrylamide for the separating gel was 
chosen as 12% so that components of the gel could be prepared according to this value. 
Two SDS-polyacrylamide gels were prepared for Bortezomib and control group 
samples in a comparative manner. As the volume of each gel was required 
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approximately 35 ml, the volume of each solution for two gels was adjusted to prepare 
80 ml of 12% SDS-polyacrylamide gel. Preparation of the separating gel and its 
components were described in Appendix B. 
 After the preparation of separating gel components, they were mixed in a 100 ml 
erlenmayer flask in the order of dH2O, acrylamide / biaacrylamide, Tris-HCl, and SDS, 
because the polymerization began as soon as the TEMED and APS were added. Thus, 
they were added to the mixture at the same time and final mixture was poured into the 
gap between glass plates without delay. After polymerization had been complete (~30 - 
45 minutes), upper side of the gels were covered with tertamyl alcohol (~500 – 600 µl) 
and they were kept overnight at 4°C.  
 
Day Three 
 
 For the equilibration, 6 ml of Equilibration buffer I was added on IPG strips 
which is in a clean rehydration tray with the gel side up position and the tray was 
carefully put on an orbital shaker for 10 minutes. Shaking was carried out in a slow 
speed to prevent the buffer from sloshing out of the tray. At the end of the incubation, 
equilibration buffer I was discarded by pouring the liquid cautiously from the tray. 
Subsequent to this, 6 ml of Equilibration buffer II containing iodoacetamide was added 
on each strip and again tray was placed to the orbital shaker for 10 minutes. End of the 
10 minutes, equilibration buffer II was discarded as mentioned before. 
 At the end of the equilibration of IPG strip, a graduated cylinder (100 ml) was 
filled with 1X Tris - Glycine - SDS running buffer and each bubble on the surface of the 
buffer was removed by the help of a Pasteur pipette. Then, the strips were sopped in the 
graduated cylinder respectively to be rinsed in the buffer. Next, each strip which was 
positioned as gel side up was laid onto the glass plate of the SDS gel, and connected 
with the gel by paying attention not to be any air bubble at the interface. Meanwhile, the 
overlay agarose solution was melted in a microwave oven by loosening the cap of the 
bottle. The glass plates were then held vertically, and the necessary amount of overlay 
agarose solution was poured into the IPG well of each gel. After each strip were pushed 
carefully using a forceps, 5 minutes was enough for agarose to be solidified. Before 
began to electrophoresis, the reservoir of the gel box and the gap between the gels were 
filled with 1X Tris - Glycine - SDS running buffer. In order to control the cooling of 
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electrophoresis, water circulation was used and electrophoresis was started at constant 
current at 32 mA for 30 minutes and followed by 50 mA for 5 – 6 hours. To monitor the 
progress of the electrophoresis, Bromophenol Blue was used. When it reached the 
bottom of the gel, electrophoresis was stopped.  
 
3.2.9.3. Staining of the Gel 
 
 A number of staining techniques have been developed to stain polypeptides with 
silver salts after separation by two-dimensional gel electrophoresis. In every case, the 
procedure based on differential reduction of silver ions that are bound to the side chains 
of amino acids (Switzer et al., 1979; Nielsen and Brown, 1984; Merril et al., 1984). 
 
 Table 3.7. Time Coarse for MALDI-TOF Compatible Mass Spectrometry 
(Source: Adapted from He et al., 2003; He et al., 2004; Lin et al., 2008) 
 
STEP SOLUTION 
TIME OF 
TREATMENT 
COMMENTS 
 
1 
 
Fixing 
(Fixer Soln.) 
40% EtOH, 
10% HAc; 
>  1 hour 
(overnight) 
Overnight incubation is 
all right 
2 Washing - - - 
 
3 
 
Sensitizing 
Pretreatment Soln. 
30% EtOH, 
4.1% NaAc, 
0.2% Na2S2O3; 
 
30 minutes 
 
Time should be exact 
4 Washing dH2O 5 min. x 3 
2
nd
 & 3
rd
 solution should 
always be fresh 
 
5 
 
Impregnate 
Silver Nitrate Solution 
0.1% AgNO3, 0.02% 
formalin; 
 
20 min. 
 
- 
 
6 
 
Washing 
 
dH2O 
 
1 min. x 2 
Time should be exact 
2
nd
 & 3
rd
 solution should 
always be fresh 
 
 
7 
 
 
Developing 
 
Developing Solution 
2.5% Na2CO3, 0.01% 
formalin 
 
 
~ 10 min. 
After a few minutes, add 
some dH2O to proceed 
the reaction slowly. Time 
should be determined by 
observation of color 
development 
8 Stop 
Stop Solution 
1.46% EDTA 
>  10 minutes 
The gels can be kept in 
this solution overnight 
9 Washing dH2O 5 min. x 3 
2
nd
 & 3
rd
 solution should 
always be fresh 
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 After electrophoresis was finished, gels were taken out from two glass plates 
cautiously into a tray for staining process. A MALDI–TOF Mass Spectrometry 
compatible silver staining method was performed. The procedure of this mass 
spectrometry suitable silver staining technique was described in Table 3.7. 
 
3.2.9.4. Image and Data Analysis of Gel 
 
After staining process, gels were scanned and photographed by OLYMPUS-
DP25 digital camera system. Then the image analysis, spot matching and determination 
of different protein spots were performed with the 7-day free licensed software package 
of DECODON Delta2D Version 4.3. The software superposed the gel photos and 
detected the differentiated protein spots. 
 According to this software the differentiated proteins were determined and cut 
from the gel to be identified by mass spectrometry. 
  
3.2.9.5. In-Gel Digestion 
 
 Differentially expressed protein spots were in-gel digested before the mass 
spectrometry analysis. In 1996, Shevchenko and his co-workers defined a protocol that 
is well suited with further identification instruments(Shevchenko, et al. 1996). Protocol 
consists of three-day procedures which an initial washing of the protein spot and 
digestion reaction are performed overnight. 
 The preparation of in-gel digestion chemicals were described in Appendix B. 
 Before beginning the in-gel digestion process, if any spots which were in a large 
size, they were diminished by the help of pipette tip. 
 
Day One: Excising and Destaining of Differentiated Protein Spots 
 
 Protein spot was excised from the gel as closely as possible with a 
sharp scalpel. To extend the surface area they were divided into 
smaller pieces. The gel pieces were put in 1.5 ml of plastic micro 
centrifuge tubes, separately.  
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 After excising the differentiated spots from the gel, they should be 
destained before the in-gel digestion procedure. The destaining of 
silver stained gels were as follows: 
 
 Following two stock solutions were prepared just prior to use. 
 
 Solution A: 2 ml of 100 mM Sodium Thiosulfate: 49.6 
mg in 2 ml ultrapure water. 
 Solution B: 2 ml of 30 mM Potassium Ferricyanide: 
19.75 mg in 2 ml ultrapure water. 
 
 Solution A and Solution B were combined in a 1:1 ratio to make 4 
ml working solution labeled as Reducing Solution. 
 200 µl Reducing Solution was added to gel tube, and destained 
until brownish color has disappeared, approximately 2 – 3 minutes. 
 Then Reducing Solution was discarded quickly from the tube, and 
500 µl ultrapure water was added to wash. Washing step was 
repeated 2 times, with 5 minutes each. 
 Finally, samples were dried in speed vacuum until completely dry, 
approximately 15 minutes. 
 
Day Two: Reduction, Alkylation, and Digestion 
Step Procedure 
 
1 
 200 μL of acetonitrile was added and the gel pieces were dehydrated 
for ~5 minutes at room temperature. When dehydrated, the gel pieces 
were an opaque white color and were smaller in size. 
2  Acetonitrile was carefully removed from the sample and discarded. 
3 
 The gel pieces were completely dried at ambient temperature in a 
vacuum centrifuge for 2-3 minutes. 
4 
 30 μL of 10 mM DTT was added and the protein was reduced for 30 
minutes at room temperature.  
5  Then, DTT was carefully removed from the sample and discarded. 
6 
 30 μL of 100 mM iodoacetamide was added and the protein was 
alkylated for 30 minutes at room temperature. 
cont. on next page 
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       Day Two: Reduction, Alkylation, and Digestion (cont.) 
7 
 Then, iodoacetamide was carefully removed from the sample and 
discarded. 
8  Step 1 was repeated 
9  Step 2 was repeated 
 
10 
 The gel pieces were rehydrated with 200 μL of 100 mM ammonium 
bicarbonate, incubating the samples for 10 minutes at room 
temperature. 
11 
 Then, ammonium bicarbonate was carefully removed from the sample 
and discarded. 
12  Step 1 was repeated 
13  Step 2 was repeated 
14  Step 3 was repeated 
 
15 
 30 μL of the trypsin solution was added to the sample and the gel 
pieces were allowed to rehydrate on ice for 10 minutes with 
occasional vortex mixing. 
16 
 The gel pieces were driven to the bottom of the tube by centrifuging 
the sample for 30 seconds. 
17 
 5 μL of 50 mM ammonium bicarbonate was added to the sample and 
the mixture was vortexed. 
18 
 The sample was driven to the bottom of the tube by centrifuging the 
sample for 30 seconds. Digestion was carried out overnight at 37ºC. 
Day Three: Extraction of Peptides for Analysis 
 
19 
 30 μL of 50 mM ammonium bicarbonate was added to the digest and 
the sample was incubated for 10 minutes with occasional gentle vortex 
mixing. 
20 
 The digest was driven to the bottom of the tube by centrifuging the 
sample for 30 seconds. 
21 
 The supernatant was carefully collected and the sample was 
transferred to a 0.5 ml plastic micro centrifuge tube. 
 
22 
 30 μL of extraction buffer was added to the tube containing the gel 
pieces and incubated for 10 minutes with occasional gentle vortex 
mixing. 
23 
 The extract was driven to the bottom of the tube by centrifuging the 
sample for 30 seconds. 
cont. on next page 
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Day Three: Extraction of Peptides for Analysis (cont.) 
24 
 The supernatant was carefully collected and combined the extract in 
the 0.5 ml plastic micro centrifuge tube. 
25  Step 22 was repeated 
26  Step 23 was repeated 
27 
 I was followed by carefully collection of supernatant and combination 
of the extract in the 0.5 ml plastic micro centrifuge tube. 
 
28 
 The volume of the extract was reduced to less than 20 μL by 
evaporation in avacuum centrifuge at ambient temperature. The 
extract must not be allowed to dry completely. 
29  The volume of the digest was adjusted to ~20 μL with acetic acid.  
30  Finally, the sample was ready for mass spectrometric analysis. 
 
3.2.9.6. ZipTip 
 
 ZipTip is a small C-18 colon used for removing salts and detergents to obtain a 
better mass signal. Protocol of ZipTip can be summarized in this manner: 
 
ZipTip 
1 Wetting 10 μl %100 ACN (Acetonitrile) 10 times 
2 Equilibration 10 μl %0.1 TFA (Trifluoroacetic acid) 10 times 
3 Sample 10 μl Our Protein Samples 10-15 times 
4 Washing 10 μl %0.1 TFA 5-6 times 
5 Elution 5 μl %0.1 TFA/%50 ACN 2-3 times 
 
3.2.9.7. Protein Identification and Mass Spectrometric Analysis 
 
 After in-gel digestion procedure, two samples (Bortezomib and Control group) 
were identified by MALDI-TOF-TOF Mass Spectrometry. The sequence of the 
diffentially expressed protein spots were found by using NCBInr (National Center for 
Biotechnology Information, Bethesda, USA) and SwissProt protein databases. 
 For mass analysis, α-cyano-4-hydroxycinnamic acid (HCCA) was used as a 
matrix. Its preparationwas described in Appendix B. 
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CHAPTER 4 
 
RESULTS AND DISCUSSION 
 
4.1. Cytotoxic Effects of Bortezomib on U-266 Cells 
 
MM U-266 cells were treated with increasing concentrations of Bortezomib for 
72 hours and XTT cell proliferation assay was carried out in order to determine the anti-
proliferative effects of agent on these cells. The cells were exposed to Bortezomib from 
0.1 to 70 nM and the results showed that there was a dose-dependent decrease in cell 
proliferation as compared to untreated controls. There were 3, 4, 15, 32, 57, 73 and 79% 
decrease of cell proliferation when the cells were exposed to 0.1, 1, 5, 10, 20, 50 and 70 
nM Bortezomib, respectively (Figure 4.1). As a result, the inhibitory concentration 
(IC50) value of Bortezomib on MM U-266 cells was calculated from cell proliferation 
plots and found to be 17 nM. (Figure 4.1).  
 
 
Figure 4.1. XTT Cell Proliferation Result 
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4.2. Changes in Caspase-3 Enzyme Activity and Loss of Mithocondrial 
Membrane Potantial) MMP 
 
To evaluate the apoptotic effects of Bortezomib on U-266 cells, Caspase-3 
enzyme activity and mitochondrial membrane potential were two important apoptotic 
indicators. Treatment of U-266 cells for 72 h with 1, 10 and 20 nM Bortezomib resulted 
in 1.06, 1.13 and 1.17-fold increases, respectively, in caspase-3 activity as compared to 
untreated controls (Figure 4.2).  
 
 
Figure 4.2. Changes in Caspase-3 Enzyme Activity 
 
We also assessed the loss of mitochondrial membrane potential in order to 
confirm the caspase-3 enzyme activity results and examine the roles of mitochondria in 
Bortezomib-induced apoptosis. Treatment of U-266 cells for 72 h with 1, 10 and 20 nM 
Bortezomib caused a significant loss of MMP (about 1.34, 1.85 and 2.14-fold, 
respectively, when compared with untreated controls), as measured by increased 
accumulation of cytoplasmic mitochondrial JC-1 (Figure 4.3). 
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Figure 4.3. Changes in Cytoplasmic/Mitochondrial JC-1 in U-266 Cells Treated with 
Bortezomib 
 
4.3. Two-Dimensional Polyacrylamide Gel Electrophoresis Results 
 
After determining the cytotoxic and apoptotic effects of Bortezomib on MM    
U-266 cells, total protein isolation was performed from Bortezomib and control group 
separately. After that isolated proteins were analyzed by Sodium Dodecyl Sulfate-
Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Two-Dimensional Gel 
Electrophoresis, respectively to identify changes in protein profiles. Protein isolation 
and 2D PAGE experiments were repeated four times. Firstly, gels obtained from 
Bortezomib and control group were stained with CBB G-250, but the results were not 
satisfactory. Then CBB R-250 and R-350 was tried with another gels and with different 
staining procedures. Finally, a mass spectrometry compatible silver staining procedure 
was applied as explained in previous chapter to increase the sensitivity, because there 
was not enough protein that was visualized on the gels after Coomassie Brillant Blue 
Staining. The gel maps belonging to two different groups (Bortezomib (treated) and 
control (untreated)) indicated a broad distribution of spots in a pI range from 3.0 to 10.0 
(Figure 4.4). 
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Figure 4.4. 2D PAGE Maps of Bortezomib (17 nM) and Control Group  
 
In order to elucidate and compare protein profiles of two groups at issue, two 
individual gel images were imported into gel analysis software DECODON Delta2D 
Version 4.3. With the help of this software, these 2D PAGE gels were superposed and 
comparative detailed analysis was performed. According to the analysis, 37 protein 
spots were differentially expressed. Among them, 5 proteins were newly formed, 10 
proteins lost, 12 proteins were up-regulated and 10 proteins were down-regulated as 
compared to control group (untreated cells) (Figure 4.4). These spots were numbered 
from 1 to 37, colored and labeled with a special name: 
 
 Newly formed proteins were marked with the green color (Y) 
 Lost proteins were marked with the red color (K) 
 Upregulated proteins were marked with the blue color (M) 
 Downregulated proteins were marked with the black color (S). 
To observe differential expressed spots easily, gels were segmented and 
magnified (Table 4.1). 
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After labeling, black and red colored spots were cut out from Control group 
while the others (green and blue ones) from Bortezomib applied group for enzymatic 
digestion by using trypsin. Then samples were analyzed by MALDI-TOF-TOF Mass 
Spectrometry and mass spectrometric data was compared to the protein database for 
sequence matches. If the amino acid sequence of a peptide could be identified, it would 
be used to find out the protein from which it was derived. In addition to this, in order to 
identify an unknown protein spot, it was necessary for a mass spectrometric analysis to 
match more than two peptide’s sequences. In our experiments, protein spot 
determination was carried out thanks to parameters such as isoelectric point, molecular 
mass, sequence coverage, and mascot mowse score, but the desired peptide matches 
were not observed. Although we cannot say that the results obtained mass spectrometric 
analysis are definite, they are the most probable results because of their parameters and 
functions. These results were shown in Table 4.2. 
 Table 4.2 summarizes the 37 differentially expressed proteins that were 
characterized. The proteins were identified as follow: 
Sixteen proteins were not identified due to some personal and instrumental 
errors during the experiment. These were Spot 1, 13, 16, 17, 19, 20, 21, 24, 26, 28, 30, 
31, 32, 33, 36 and 37, namely M1S, S4Cb, K3C, K4C, M6S, M7S, M8S, K6C, S8C, 
S10C, M10Sc, M10Sb, M10Sa, K8Cb and K8Ca, respectively. 
Spot 2, Caspase-3 is involved in the activation cascade of caspases responsible 
for apoptosis execution. At the onset of apoptosis, it proteolytically cleaves poly (ADP-
ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' bond and activates sterol 
regulatory element binding proteins (SREBPs) between the basic helix-loop-helix 
leucine zipper domain and the membrane attachment domain. Additionally, it cleaves 
and activates caspase-6, -7 and -9. Caspase-3 found in many cell lines, highest 
expression in cells of the immune system. Because of its function and role in apoptosis, 
after applying Bortezomib (17 nM) to MM U-266 cells, the increasing expression level 
of this protein was expected results. 
Spot 3 were signed to uncharacterized protein C7orf46. Although its function 
does not know exactly, it is thought that this protein may be involved in alternative 
splicing.  
Spot 18, C-type lectin domain family 5 member A has a function as a positive 
regulator of osteoclastogenesis. Thus, it was upregulated after the cells exposed to 
Bortezomib.   
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Table 4.2. Results of Differential Proteins Identified MALDI-TOF Mass Spectrometry 
Spot 
No 
Spot 
Name 
 
Protein Identity 
 
Matched Peptides 
Sequence 
Coverage 
(%) 
Mascot 
Mowse 
Score 
Nominal 
Mass/pI 
(kDa) 
1 M1S Unidentified - - - - 
 
 
 
2 
 
 
 
M2S 
 
 
CASP3  
Caspase-3  
MENTENSVDSKSIKNLEPKIIHGSESMDSGISLDNSYKMDYPEMGLCIIINNKNFHKST
GMTSRSGDVDAANLRETFRNLKYEVRNKNDLTREEIVELMRDVSKEDHSKRSSFVCV
LLSHGEEGIIFGTNGPVDLKKITNFFRGDRCRSLTGKPKLFIIQACRGTELDCGIETDS
GVDDDMACHKIPVEADFLYAYSTAPGYYSWRNSKDGSWFIQSLCAMLKQYADKLEF
MHILTRVNRKVATEFESFSFDATFHAKK QIPCIVSMLTKELYFYH 
 
 
 
6% 
 
 
 
20 
 
 
 
31.5/6.09 
 
 
 
3 
 
 
 
M3S 
 
 
CG046 
Uncharacterized 
proteinC7orf46 
MERLTLPLGGAAAVDEYLEYRRIVGEDDGGKLFTPEEYEEYKRKVLPLRLQNRLFV
SWRSPTGMDCKLVGPETLCFCTHRYKQHKTDLEAIPQQCPIDLPCQVTGCQCRAYL
YVPLNGSQPIRCRCKHFADQHSAAPGFTCNTCSKCSGFHSCFTCACGQPAYAHDTVV
ETKQERLAQEKPVGQDIPYAAMGGLTGFSSLAEGYMRLDDSGIGVPSVEFLESPITAV
DSPFLKAFQASSSSSPETLTDVGTSSQVSSLRRPEEDDMAFFERRYQERMKMEKAAK
WKGKAPLPSATKPS 
 
 
 
7% 
 
 
 
21 
 
 
 
33.0/6.33 
 
 
4 
 
 
M4S 
UBE2C  
Ubiquitin-
conjugating enzyme 
E2C  
MASQNRDPAATSVAAARKGAEPSGGAARGPVGKRLQQELMTLMMSGDKGISAFPES
DNLFKWVGTIHGAAGTVYEDLRYKLSLEFPSGYPYNAPTVKFLTPCYHPNVDTQGNI
CLDILKEKWSALYDVRTILLSIQSLLGEPNIDSPLNTHAAELWKNPTAFKKYLQETYS
KQVTSQEP 
 
 
6% 
 
 
21 
 
 
19.6/6.82 
 
 
 
 
 
 
5 
 
 
 
 
 
 
K1C 
 
 
 
 
 
 
PAXI 
(Paxillin) 
MDDLDALLADLESTTSHISKRPVFLSEETPYSYPTGNHTYQEIAVPPPVPPPPSSEALN
GTILDPLDQWQPSSSRFIHQQPQSSSPVYGSSAKTSSVSNPQDSVGSPCSRVGEEEHVY
SFPNKQKSAEPSPTVMSTSLGSNLSELDRLLLELNAVQHNPPGFPADEANSSPPLPGAL
SPLYGVPETNSPLGGKAGPLTKEKPKRNGGRGLEDVRPSVESLLDELESSVPSPVPAI
TVNQGEMSSPQRVTSTQQQTRISASSATRELDELMASLSDFKIQGLEQRADGERCWA
AGWPRDGGRSSPGGQDEGGFMAQGKTGSSSPPGGPPKPGSQLDSMLGSLQSDLNKL
GVATVAKGVCGACKKPIAGQVVTAMGKTWHPEHFVCTHCQEEIGSRNFFERDGQP
YCEKDYHNLFSPRCYYCNGPILDKVVTALDRTWHPEHFFCAQCGAFFGPEGFHEKD
GKAYCRKDYFDMFAPKCGGCARAILENYISALNTLWHPECFVCRECFTPFVNGSFFE
HDGQPYCEVHYHERRGSLCSGCQKPITGRCITAMAKKFHPEHFVCAFCLKQLNKGT
FKEQNDKPYCQNCFLKLFC 
 
 
 
 
 
 
2% 
 
 
 
 
 
 
1 
 
 
 
 
 
 
64.4/5.80 
 
 
6 
 
 
Y1S 
 
GPX3 
Glutathione 
peroxidase 3 
MARLLQASCLLSLLLAGFVSQSRGQEKSKMDCHGGISGTIYEYGALTIDGEEYIPFKQ
YAGKYVLFVNVASYUGLTGQYIELNALQEELAPFGLVILGFPCNQFGKQEPGENSEIL
PTLKYVRPGGGFVPNFQLFEKGDVNGEKEQKFYTFLKNSCPPTSELLGTSDRLFWEP
MKVHDIRWNFEKFLVGPDGIPIMRWHHRTTVSNVKMDILSYMRRQAALGVKRK 
 
 
6% 
 
 
21 
 
 
25.5/8.26 
cont. on next page 
 
7
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Table 4.2. Results of Differential Proteins Identified MALDI-TOF Mass Spectrometry (cont.) 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
 
 
 
 
 
 
 
 
 
 
 
Y2S 
 
 
 
 
 
M4K1  
Mitogen-activated 
protein kinase 
kinase kinase kinase 
1 
MDVVDPDIFNRDPRDHYDLLQRLGGGTYGEVFKARDKVSGDLVALKMVKMEPDDD
VSTLQKEILILKTCRHANIVAYHGSYLWLQKLWICMEFCGAGSLQDIYQVTGSLSEL
QISYVCREVLQGLAYLHSQKKIHRDIKGANILINDAGEVRLADFGISAQIGATLARRLS
FIGTPYWMAPEVAAVALKGGYNELCDIWSLGITAIELAELQPPLFDVHPLRVLFLMT
KSGYQPPRLKEKGKWSAAFHNFIKVTLTKSPKKRPSATKMLSHQLVSQPGLNRGLIL
DLLDKLKNPGKGPSIGDIEDEEPELPPAIPRRIRSTHRSSSLGIPDADCCRRHMEFRKL
RGMETRPPANTARLQPPRDLRSSSPRKQLSESSDDDYDDVDIPTPAEDTPPPLPPKPKF
RSPSDEGPGSMGDDGQLSPGVLVRCASGPPPNSPRPGPPPSTSSPHLTAHSEPSLWNPP
SRELDKPPLLPPKKEKMKRKGCALLVKLFNGCPLRIHSTAAWTHPSTKDQHLLLGA
EEGIFILNRNDQEATLEMLFPSRTTWVYSINNVLMSLSGKTPHLYSHSILGLLERKET
RAGNPIAHISPHRLLARKNMVSTKIQDTKGCRACCVAEGASSGGPFLCGALETSVVL
LQWYQPMNKFLLVRQVLFPLPTPLSVFALLTGPGSELPAVCIGVSPGRPGKSVLFHT
VRFGALSCWLGEMSTEHRGPVQVTQVEEDMVMVLMDGSVKLVTPEGSPVRGLRTP
EIPMTEAVEAVAMVGGQLQAFWKHGVQVWALGSDQLLQELRDPTLTFRLLGSPRL
ECSGTISPHCNLLLPGSSNSPASASRVAGITGL 
 
 
 
 
 
 
 
1% 
 
 
 
 
 
 
 
11 
 
 
 
 
 
 
 
91.2/8.65 
 
 
 
SMAD7  
Mothers against 
decapentaplegic 
homolog 7 
 
MFRTKRSALVRRLWRSRAPGGEDEEEGAGGGGGGGELRGEGATDSRAHGAGGGG
PGRAGCCLGKAVRGAKGHHHPHPPAAGAGAAGGAEADLKALTHSVLKKLKERQLE
LLLQAVESRGGTRTACLLLPGRLDCRLGPGAPAGAQPAQPPSSYSLPLLLCKVFRWP
DLRHSSEVKRLCCCESYGKINPELVCCNPHHLSRLCELESPPPPYSRYPMDFLKPTAD
CPDAVPSSAETGGTNYLAPGGLSDSQLLLEPGDRSHWCVVAYWEEKTRVGRLYCVQ
EPSLDIFYDLPQGNGFCLGQLNSDNKSQLVQKVRSKIGCGIQLTREVDGVWVYNRSS
YPIFIKSATLDNPDSRTLLVHKVFPGFSIKAFDYEKAYSLQRPNDHEFMQQPWTGFTV
QISFVKGWGQCYTRQFISSCPCWLEVIFNSR 
 
 
 
 
3% 
 
 
 
 
18 
 
 
 
 
46.3/8.63 
 
 
 
 
 
 
 
 
8 
 
 
 
 
 
 
 
 
Y3S 
 
 
 
 
 
 
 
ST7  
Suppressor of 
tumorigenicity 7 
protein 
MAEAATGFLEQLKSCIVWSWTYLWTVWFFIVLFLVYILRVPLKINDNLSTVSMFLNT
LTPKFYVALTGTSSLISGLILIFEWWYFRKYGTSFIEQVSVSHLRPLLGGVDNNSSNNS
NSSNGDSDSNRQSVSECKVWRNPLNLFRGAEYNRYTWVTGREPLTYYDMNLSAQDH
QTFFTCDSDHLRPADAIMQKAWRERNPQARISAAHEALEINEIRSRVEVPLIASSTIWE
IKLLPKCATAYILLAEEEATTIAEAEKLFKQALKAGDGCYRRSQQLQHHGSQYEAQH
RRDTNVLVYIKRRLAMCARRLGRTREAVKMMRDLMKEFPLLSMFNIHENLLEALLE
LQAYADVQAVLAKYDDISLPKSATICYTAALLKARAVSDKFSPEAASRRGLSTAEMN
AVEAIHRAVEFNPHVPKYLLEMKSLILPPEHILKRGDSEAIAYAFFHLAHWKRVEGA
LNLLHCTWEGTFRMIPYPLEKGHLFYPYPICTETADRELLPSFHEVSVYPKKELPFFI
LFTAGLCSFTAMLALLTHQFPELMGVFAKAMIDIFCSAEFRDWNCKSIFMRVEDELE
IPPAPQSQHFQN 
 
 
 
 
 
6% 
 
 
 
 
 
24 
 
 
 
 
 
67.1/6.82 
cont. on next page 
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Table 4.2. Results of Differential Proteins Identified MALDI-TOF Mass Spectrometry (cont.) 
 
 
 
 
 
 
 
 
 
 
 
9 
 
 
 
 
 
 
 
 
 
 
S1C 
BST2  
Bone marrow 
stromal antigen 2 
MASTSYDYCRVPMEDGDKRCKLLLGIGILVLLIIVILGVPLIIFTIKANSEACRDGLRA
VMECRNVTHLLQQELTEAQKGFQDVEAQAATCNHTVMALMASLDAEKAQGQKKV
EELEGEITTLNHKLQDASAEVERLRRENQVLSVRIADKKYYPSSQDSSSAAAPQLLIV
LLGLSALLQ 
 
 
9% 
 
 
22 
 
 
19.7/5.43 
 
 
 
 
 
 
 
NFKB1 
Nuclear factor NF-
kappa-B p105 
subunit 
MAEDDPYLGRPEQMFHLDPSLTHTIFNPEVFQPQMALPTDGPYLQILEQPKQRGFRF
RYVCEGPSHGGLPGASSEKNKKSYPQVKICNYVGPAKVIVQLVTNGKNIHLHAHSLV
GKHCEDGICTVTAGPKDMVVGFANLGILHVTKKKVFETLEARMTEACIRGYNPGLL
VHPDLAYLQAEGGGDRQLGDREKELIRQAALQQTKEMDLSVVRLMFTAFLPDSTGS
FTRRLEPVVSDAIYDSKAPNASNLKIVRMDRTAGCVTGGEEIYLLCDKVQKDDIQIRF
YEEEENGGVWEGFGDFSPTDVHRQFAIVFKTPKYKDINITKPASVFVQLRRKSDLETS
EPKPFLYYPEIKDKEEVQRKRQKLMPNFSDSFGGGSGAGAGGGGMFGSGGGGGGT
GSTGPGYSFPHYGFPTYGGITFHPGTTKSNAGMKHGTMDTESKKDPEGCDKSDDKN
TVNLFGKVIETTEQDQEPSEATVGNGEVTLTYATGTKEESAGVQDNLFLEKAMQLA
KRHANALFDYAVTGDVKMLLAVQRHLTAVQDENGDSVLHLAIIHLHSQLVRDLLEV
TSGLISDDIINMRNDLYQTPLHLAVITKQEDVVEDLLRAGADLSLLDRLGNSVLHLAA
KEGHDKVLSILLKHKKAALLLDHPNGDGLNAIHLAMMSNSLPCLLLLVAAGADVNA
QEQKSGRTALHLAVEHDNISLAGCLLLEGDAHVDSTTYDGTTPLHIAAGRGSTRLAA
LLKAAGADPLVENFEPLYDLDDSWENAGEDEGVVPGTTPLDMATSWQVFDILNGKP
YEPEFTSDDLLAQGDMKQLAEDVKLQLYKLLEIPDPDKNWATLAQKLGLGILNNAF
RLSPAPSKTLMDNYEVSGGTVRELVEALRQMGYTEAIEVIQAASSPVKTTSQAHSLPL
SPASTRQQIDELRDSDSVCDSGVETSFRKLSFTESLTSGASLLTLNKMPHDYGQEGPL
EGKI 
 
 
 
 
 
 
 
 
1% 
 
 
 
 
 
 
 
 
13 
 
 
 
 
 
 
 
 
105.2/5.20 
 
 
 
 
10 
 
 
 
 
S2C 
 
 
MKNK1  
MAP kinase-
interacting 
serine/threonine-
protein kinase 1 
MVSSQKLEKPIEMGSSEPLPIADGDRRRKKKRRGRATDSLPGKFEDMYKLTSELLGE
GAYAKVQGAVSLQNGKEYAVKIIEKQAGHSRSRVFREVETLYQCQGNKNILELIEFF
EDDTRFYLVFEKLQGGSILAHIQKQKHFNEREASRVVRDVAAALDFLHTKDKVSLCH
LGWSAMAPSGLTAAPTSLGSSDPPTSASQVAGTTGIAHRDLKPENILCESPEKVSPVKI
CDFDLGSGMKLNNSCTPITTPELTTPCGSAEYMAPEVVEVFTDQATFYDKRCDLWSL
GVVLYIMLSGYPPFVGHCGADCGWDRGEVCRVCQNKLFESIQEGKYEFPDKDWAHI
SSEAKDLISKLLVRDAKQRLSAAQVLQHPWVQGQAPEKGLPTPQVLQRNSSTMDLT
LFAAEAIALNRQLSQHEENELAEEPEALADGLCSMKLSPPCKSRLARRRALAQAGRG
EDRSPPTAL 
 
 
 
 
2% 
 
 
 
 
15 
 
 
 
 
51.3/6.26 
 
11 
 
S3C 
SOCS3 Suppressor 
of cytokine signaling 
3 
MVTHSKFPAAGMSRPLDTSLRLKTFSSKSEYQLVVNAVRKLQESGFYWSAVTGGEA
NLLLSAEPAGTFLIRDSSDQRHFFTLSVKTQSGTKNLRIQCEGGSFSLQSDPRSTQPVP
RFDCVLKLVHHYMPPPGAPSFPSPPTEPSSEVPEQPSAQPLPGSPPRRAYYIYSGGEKI
PLVLSRPLSSNVATLQHLCRKTVNGHLDSYEKVTQLPGPIREFLDQYDAPL 
 
7% 
 
23 
 
24.7/8.98 
cont. on next page 
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Table 4.2. Results of Differential Proteins Identified MALDI-TOF Mass Spectrometry (cont.) 
 
 
 
12 
 
 
S4Ca 
TN13B 
Tumor necrosis 
factor ligand 
superfamily member 
13B 
MDDSTEREQSRLTSCLKKREEMKLKECVSILPRKESPSVRSSKDGKLLAATLLLALLS
CCLTVVSFYQVAALQGDLASLRAELQGHHAEKLPAGAGAPKAGLEEAPAVTAGLKI
FEPPAPGEGNSSQNSRNKRAVQGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSF
KRGSALEEKENKILVKETGYFFIYGQVLYTDKTYAMGHLIQRKKVHVFGDELSLVTL
FRCIQNMPETLPNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVTFFGALKLL 
 
 
2% 
 
 
5 
 
 
31.2/5.93 
13 S4Cb Unidentified - - - - 
 
 
14 
 
 
K9C 
SIT1  
Signaling trashold-
regulating 
transmembrane 
adapter 1 
MNQADPRLRAVCLWTLTSAAMSRGDNCTDLLALGIPSITQAWGLWVLLGAVTLLFL
ISLAAHLSQWTRGRSRSHPGQGRSGESVEEVPLYGNLHYLQTGRLSQDPEPDQQDPT
LGGPARAAEEVMCYTSLQLRPPQGRIPGPGTPVKYSEVVLDSEPKSQASGPEPELYAS
VCAQTRRARASFPDQAYAN SQPAAS 
 
 
9% 
 
 
22 
 
 
21.1/5.91 
 
 
 
 
 
 
 
 
15 
 
 
 
 
 
 
 
 
K2C 
 
 
 
 
 
 
 
CAR14 
Caspase recruitment 
domain-containing 
protein 14 
MGELCRRDSALTALDEETLWEMMESHRHRIVRCICPSRLTPYLRQAKVLCQLDEEE
VLHSPRLTNSAMRAGHLLDLLKTRGKNGAIAFLESLKFHNPDVYTLVTGLQPDVDFS
NFSGLMETSKLTECLAGAIGSLQEELNQEKGQKEVLLRRCQQLQEHLGLAETRAEG
LHQLEADHSRMKREVSAHFHEVLRLKDEMLSLSLHYSNALQEKELAASRCRSLQEE
LYLLKQELQRANMVSSCELELQEQSLRTASDQESGDEELNRLKEENEKLRSLTFSLA
EKDILEQSLDEARGSRQELVERIHSLRERAVAAERQREQYWEEKEQTLLQFQKSKM
ACQLYREKVNALQAQVCELQKERDQAYSARS 
AQREISQSLVEKDSLRRQVFELTDQVCELRTQLRQLQAEPPGVLKQEARTREPCPRE
KQRLVRMHAICPRDDSDCSLVSSTESQLLSDLSATSSRELVDSFRSSSPAPPSQQSLYK
RVAEDFGEEPWSFSSCLEIPEGDPGALPGAKAGDPHLDYELLDTADLPQLESSLQPVS
PGRLDVSESGVLMRRRPARRILSQVTMLAFQGDALLEQISVIGGNLTGIFIHRVTPGS
AADQMALRPGTQIVMVDYEASEPLFKAVLEDTTLEEAVGLLRRVDGFCCLSVKVNT
DGYKRLLQDLEAKVATSGDSFYIRVNLAMEGRAKGELQVHCNEVLHVTDTMFQGC
GCWHAHRVNSYTMKDTAAHGTIPNYSRAQQQLIALIQDMTQQCTVTRKPSSGGPQK
LVRIVSMDKAKASPLRLSFDRGQLDPSRMEGSSTCFWAESCLTLVPYTLVRPHRPAR
PRPVLLVPRAVGKILSEKLCLLQGFKKCLAEYLSQEEYEAWSQRGDIIQEGEVSGGR
CWVTRHAVESLMEKNTHALLDVQLDSVCTLHRMDIFPIVIHVSVNEKMAKKLKKGL
QRLGTSEEQLLEAARQEEGDLDRAPCLYSSLAPDGWSDLDGLLSCVRQAIADEQKK
VVWTEQSPR 
 
 
 
 
 
 
 
 
1% 
 
 
 
 
 
 
 
 
11 
 
 
 
 
 
 
 
 
113.1/5.65 
16 K3C Unidentified - - - - 
17 K4C Unidentified - - - - 
cont. on next page 
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Table 4.2. Results of Differential Proteins Identified MALDI-TOF Mass Spectrometry (cont.) 
 
 
18 
 
M5S 
CLC5A  
C-type lectin domain 
family 5 member A 
MNWHMIISGLIVVVLKVVGMTLFLLYFPQIFNKSNDGFTTTRSYGTVSQIFGSSSPSPN
GFITTRSYGTVCPKDWEFYQARCFFLSTSESSWNESRDFCKGKGSTLAIVNTPEKLKF
LQDITDAEKYFIGLIYHREEKRWRWINNSVFNGNVTNQNQNFNCATIGLTKTFDAAS
CDISYRRICEKNAK 
 
6% 
 
21 
 
21.5/9.04 
19 M6S Unidentified 
- 
- - - 
20 M7S Unidentified 
- 
- - - 
21 M8S Unidentified 
- 
- -  
 
 
22 
 
 
S5C 
 
CHIP 
E3 ubiquitin-protein 
ligase CHIP 
MKGKEEKEGGARLGAGGGSPEKSPSAQELKEQGNRLFVGRKYPEAAACYGRAITRP
LVAVYYTNRALCYLKQQHEQALADCRRALELDGQSVKAHFFLGQCQLEMESYDEAI
ANLQRAYSLAKEQRLNFGDDIPSALRIAKKKRWNSIEERRIHQESELHSYLSRLIAAE
RERELEECQRNHEGDEDDSHVRAQQACIEAKHDKYMADMDELFSQVDEKRKKRDI
PDYLCGKISFELMREPCITPSGITYDRKDIEEHLQRVGHFDPVTRSPLTQEQLIPNLAM
KEVIDAFISENGWVEDY 
 
 
7% 
 
 
22 
 
 
34.8/5.61 
 
 
 
23 
 
 
 
K5C 
 
 
IKBD  
NF-kappa-B 
inhibitor delta 
MEAGPWRVSAPPSGPPQFPAVVPGPSLEVARAHMLALGPQQLLAQDEEGDTLLHLF
AARGLRWAAYAAAEVLQVYRRLDIREHKGKTPLLVAAAANQPLIVEDLLNLGAEPN
AADHQGRSVLHVAATYGLPGVLLAVLNSGVQVDLEARDFEGLTPLHTAILALNVAM
RPSDLCPRVLSTQARDRLDCVHMLLQMGANHTSQEIKSNKTVLHLAVQAANPTLVQ
LLLELPRGDLRTFVNMKAHGNTALHMAAALPPGPAQEAIVRHLLAAGADPTLRNLE
NEQPVHLLRPGPGPEGLRQLLKRSRVAPPG LSS 
 
 
 
3% 
 
 
 
3 
 
 
 
33.4/6.90 
24 K6C Unidentified 
- 
- - - 
 
 
25 
 
 
S6C 
TNR17  
Tumor necrosis 
factor receptor 
superfamily member 
17 
MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNAILW
TCLGLSLIISLAVFVLMFLLRKINSEPLKDEFKNTGSGLLGMANIDLEKSRTGDEIILP
RGLEYTVEECTCEDCIKSKPKVDSDHCFPLPAME  
EGATILVTTKTNDYCKSLPAALSATEIEKSISAR 
 
 
6% 
 
 
21 
 
 
20.1/5.24 
26 K7C Unidentified 
- 
- - - 
cont. on next page 
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Table 4.2. Results of Differential Proteins Identified MALDI-TOF Mass Spectrometry (cont.) 
 
 
 
27 
 
 
Y5S 
SIVA  
Apoptosis 
Regulatory Protein 
Siva 
MPKRSCPFADVAPLQLKVRVSQRELSRGVCAERYSQEVFEKTKRLLFLGAQAYLDH
VWDEGCAVVHLPESPKPGPTGAPRAARGQMLIGPDGRLIRSLGQASEADPSGVA 
SIACSSCVRAVDGKAVCGQCERALCGQCVRTCWGCGSVACTLCGLVDCSDMYEKV
LCTSCAMFET 
 
 
14% 
 
 
25 
 
 
18.6/7.86 
28 S8C Unidentified 
- 
- - - 
 
 
 
 
 
 
29 
 
 
 
 
 
 
S9C 
PYDC1  
Pyrin domain-
containing protein 1 
MGTKREAILKVLENLTPEELKKFKMKLGTVPLREGFERIPRGALGQLDIVDLTDKLV
ASYYEDYAAELVVAVLRDMRMLEEAARLQRAA 
 
17% 
 
25 
 
10.1/6.29 
 
PSB3  
Proteasome subunit 
beta type-3 
MSIMSYNGGAVMAMKGKNCVAIAADRRFGIQAQMVTTDFQKIFPMGDRLYIGLAG
LATDVQTVAQRLKFRLNLYELKEGRQIKPYTLMSMVANLLYEKRFGPYYTEPVIA 
GLDPKTFKPFICSLDLIGCPMVTDDFVVSGTCAEQMYGMCESLWEPNMDPDHLFETI
SQAMLNAVDRDAVSGMGVIVHIIEKDKITTRTLKARMD 
 
 
12% 
 
 
14 
 
 
22.9/6.14 
 
LY6K Lymphocyte 
antigen 6K 
MALLALLLVVALPRVWTDANLTARQRDPEDSQRTDEGDNRVWCHVCERENTFECQ
NPRRCKWTEPYCVIAAVKIFPRFFMVAKQCSAGCAAMERPKPEEKRFLLEEPMPFFY
LKCCKIRYCNLEGPPINSSVFKEYAGSMGESCGGLWLAILLLLASIAAGLSLS 
 
 
10% 
 
 
3 
 
 
18.6/7.44 
30 S10C Unidentified 
- 
- - - 
31 M10Sc Unidentified 
- 
- - - 
32 M10Sb Unidentified 
- 
- - - 
33 M10Sa Unidentified 
- 
- - - 
 
 
34 
 
 
M9S 
 
RAB25 
(Ras-related protein 
Rab-25) 
MGNGTEEDYNFVFKVVLIGESGVGKTNLLSRFTRNEFSHDSRTTIGVEFSTRTVMLG
TAAVKAQIWDTAGLERYRAITSAYYRGAVGALLVFDLTKHQTYAVVERWLKELYD
HAEATIVVMLVGNKSDLSQAREVPTEEARMFAENNGLLFLETSALDSTNVELAFETV
LKEIFAKVSKQRQNSIRTNAITLGSAQAGQEPGPGEKRACCISL 
 
 
4% 
 
 
1 
 
 
23.4/5.72 
cont. on next page 
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Table 4.2. Results of Differential Proteins Identified MALDI-TOF Mass Spectrometry (cont.) 
 
 
 
 
 
 
35 
 
 
 
 
 
Y4S 
RAB43  
Ras-related protein 
Rab-43 
MAGPGPGPGDPDEQYDFLFKLVLVGDASVGKTCVVQRFKTGAFSERQGSTIGVDFT
MKTLEIQGKRVKLQIWDTAGQERFRTITQSYYRSANGAILAYDITKRSSFLSVPHWIE
DVRKYAGSNIVQLLIGNKSDLSELREVSLAEAQSLAEHYDILCAIETSAKDSSNVEEAF
LRVATELIMRHGGPLFS EKSPDHIQLNSKDIGEGWGCGC 
 
11% 
 
24 
 
23.3/5.44 
 
IL32 Interleukin-32 
MCFPKVLSDDMKKLKARMVMLLPTSAQGLGAWVSACDTEDTVGHLGPWRDKDPA
LWCQLCLSSQHQAIERFYDKMQNAESGRGQVMSSLAELEDDFKEGYLETVAAYYEE
QHPELTPLLEKERDGLRCRGNRSPVPDVEDPATEEPGESFCDKVMRWFQAMLQRLQ
TWWHGVLAWVKEKVVALVHAVQALWKQFQSFCCSLSELFMSSFQSYGAPRGDKEE
LTPQKCSEPQSSK 
 
10% 
 
23 
 
26.6/5.14 
MYL6  
Myosin light 
polypeptide 6 
MCDFTEDQTAEFKEAFQLFDRTGDGKILYSQCGDVMRALGQNPTNAEVLKVLGNPK
SDEMNVKVLDFEHFLPMLQTVAKNKDQGTYEDYVEGLRVFDKEGNGTVMGAEIRH
VLVTLGEKMTEEEVEMLVAGHEDSNGCINYEAFVRHILSG 
 
15% 
 
24 
 
16.9/4.56 
36 K8Cb Unidentified - - - - 
37 K8Ca Unidentified - - - - 
 
8
3
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Spot 4, Ubiquitin-conjugating enzyme E2C accepts ubiquitin from the E1 
complex and catalyzes its covalent attachment to other proteins. It catalyzes 'Lys-11'- 
and 'Lys-48'-linked polyubiquitination in vitro. Morover this protein acts as an essential 
factor of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated 
ubiquitin ligase that controls progression through mitosis. Acts by initiating 'Lys-11'-
linked polyubiquitin chains on APC/C substrates, leading to the degradation of APC/C 
substrates by the proteasome and promoting mitotic exit. As this protein is responsible 
for controlling progression and has a role in protein ubiquitination, its expression level 
is increasing with the Bortezomib effect. 
 Spot 34, Ras-related protein Rab-25 is involved in the regulation of cell survival. 
Similar to spot 2, 4, and 18, its expression degree increases in response to Bortezomib. 
 Spot 5, Paxillin is a cytoskeletal protein involved in actin-membrane attachment 
at sites of cell adhesion to the extracellular matrix (focal adhesion). With the applying 
anticancer agents to the cells, it was lost. 
 Spot 14, Signaling trashold-regulating transmembrane adapter 1 negatively 
regulates TCR (T-cell antigen receptor)-mediated signaling in T-cells. It is also involved 
in positive selection of T-cells. It is specifically expressed in T and B-cells and present 
in plasma cells but not in germinal center B-cells (at protein level). Furthermore, it is 
expressed in T- and B-cell lymphoma. Like spot 5, it was lost with the Bortezomib. 
 Spot 15, Caspase recruitment domain-containing protein 14 activates NF-κB via 
BCL10 and IKK and stimulates the phosphorylation of BCL10. The main goal of 
Bortezomib is inhibit the proteasomes for preventing the IκB degredation and 
accordingly NF-κB activation, so it is very required to lose of this protein as expected. 
 Spot 23, NF-κB inhibitor delta may regulate the expression of IL-2, IL-6, and 
other cytokines through regulation on NF-κB activity, similarly to spot 15.  
 Spot 6, Glutathione peroxidase 3 protects cells and enzymes from oxidative 
damage, by catalyzing the reduction of hydrogen peroxide, lipid peroxides and organic 
hydroperoxide, by glutathione. So, it is an example of newly formed protein after the 
Bortezomib effects upon MM U-266 cells. 
 For spot 7, we obtained two proteins that have the change to be the correct one 
after the mass spectrometric analysis. One of them was Mitogen-activated protein 
kinase kinase kinase kinase 1 which may play a role in the response to environmental 
stress. This protein appears to act upstream of the JUN N-terminal pathway and might 
play a role in hematopoietic lineage decisions and growth regulation. As well as, it is 
 85 
 
expressed primarily in hematopoietic organs especially bone marrow. After the 
Bortezomib, the afore-mentioned protein came to light to carry out its function. The 
other protein was Mothers against decapentaplegic homolog 7 that is involved in cell 
signaling. 
 Spot 8, Suppressor of tumorigenicity 7 protein may act as a tumor suppressor. It 
is another newly formed protein.  
 Spot 27, Apoptosis Regulatory Protein Siva induces CD27-mediated apoptosis 
and inhibits BCL2L1 isoform Bcl-x(L) anti-apoptotic activity. It is also inhibits 
activation of NF-κB and promotes T-cell receptor-mediated apoptosis. So, generation of 
this protein after the Bortezomib stress is vital for cancerous cells. 
 Spot 35 has three opportunities since it did not determine exactly. One of them 
was Ras-related protein Rab-43. The others were Interleukin-32 and Myosin light 
polypeptide 6. IL-32 is a cytokine that may play a role in innate and adaptive immune 
responses. It induces various cytokines such as TNFA/TNF-alpha and IL8 and activates 
typical cytokine signal pathways of NF-κB and p38 MAPK.  
 Spot 9 has two alternatives: Bone marrow stromal antigen 2 and NF-κB p105 
subunit. First protein may be involved in the sorting of secreted proteins and pre-B-cell 
growth. Also it may play a role in B-cell activation. NF-κB is a pleiotropic transcription 
factor which is present in almost all cell types and is involved in many biological 
processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis 
and apoptosis. NF-κB is a homo- or heterodimeric complex formed by the Rel-like 
domain-containing proteins RELA/p65, RELB, NFKB1/p105, NF-κB1/p50, REL and 
NF-κB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. 
The dimers bind at κB sites in the DNA of their target genes and the individual dimers 
have distinct preferences for different κB sites that they can bind with distinguishable 
affinity and specificity. Different dimer combinations act as transcriptional activators or 
repressors, respectively. NF-κB is controlled by various mechanisms of post-
translational modification and subcellular compartmentalization as well as by 
interactions with other cofactors or corepressors. NF-κB complexes are held in the 
cytoplasm in an inactive state complexed with members of the NF-κB inhibitor (IκB) 
family. In a conventional activation pathway, IκB is phosphorylated by IκB kinases 
(IKKs) in response to different activators, subsequently degraded thus liberating the 
active NF-κB complex which translocates to the nucleus. NF-κB heterodimeric p65-p50 
and RelB-p50 complexes are transcriptional activators. The NF-κB p50-p50 homodimer 
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is a transcriptional repressor, but can act as a transcriptional activator when associated 
with BCL3. NF-κB1 appears to have dual functions such as cytoplasmic retention of 
attached NF-κB proteins by p105 and generation of p50 by a cotranslational processing. 
The proteasome-mediated process ensures the production of both p50 and p105 and 
preserves their independent function, although processing of NF-κB1/p105 also appears 
to occur post-translationally. p50 binds to the κB consensus sequence 5'-
GGRNNYYCC-3', located in the enhancer region of genes involved in immune 
response and acute phase reactions. In a complex with MAP3K8, NF-κB1/p105 
represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by 
proteasome-dependent degradation of NF-κB1/p105. 
 Spot 10, MAP kinase-interacting serine/threonine-protein kinase 1 may play a 
role in the response to environmental stress and cytokines. 
 Spot 11, Suppressor of cytokine signaling 3 is a SOCS family protein. It forms 
part of a classical negative feedback system that regulates cytokine signal transduction. 
SOCS3 is involved in negative regulation of cytokines that signal through the 
JAK/STAT pathway. 
 Spot 12, Tumor necrosis factor ligand superfamily member 13B promotes the 
survival of mature B-cells and the B-cell response. 
 Spot 22, E3 ubiquitin-protein ligase CHIP which targets misfolded chaperone 
substrates towards proteasomal degradation. It has a central role in protein modification 
and protein ubiquitination. 
 Spot 25, Tumor necrosis factor receptor superfamily member 17 promotes B-cell 
survival and plays a role in the regulation of humoral immunity and activates NF-κB 
and JNK. It is expressed in mature B-cells. 
 Spot 29 did not identified clearly. Pyrin domain-containing protein 1 associates 
with apoptosis-associated specklike protein containing a CARD domain and modulates 
its ability to collaborate with pyrin and cryopyrin in NF-κB and procaspase-1 activation. 
Suppresses kinase activity of NF-κB inhibitor kinase (IκK) complex, expression of NF-
κB inducible genes and inhibits NF-κB activation by cytokines. Proteasome subunit 
beta type-3 is a multicatalytic proteinase complex which is characterized by its ability to 
cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at 
neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. 
Lymphocyte antigen 6K may play a role in cell growth. After Bortezomib was applied 
onto MM U-266 cells, spot 9, 10, 11, 12, 22, 25, and 29 were down regulated. 
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CHAPTER 5 
 
CONCLUSIONS 
 
Multiple Myeloma is a malignant plasma cell disorder and the second most 
common hematological disorder (Dalton et al., 2001). Unfortunately, its incidence is 
increasing day by day. Chemical agents and natural products which may have strong 
anticancer potential always attract the attention of clinicians and basic science 
researchers. Bortezomib is one of them, known as proteasome inhibitor that has entered 
clinical trials for Multiple Myeloma (Mateos and Miguel., 2007). Until now, the effect 
mechanism of Bortezomib on Multiple Myeloma has been tried to explain by molecular 
level but, to the best of our knowledge, there is no any studies has been pursued about 
the changes in protein profiles of Bortezomib applied Multiple Myeloma cells (U-266) 
in the literature. It has a vital significance to investigate protein profiles in terms of 
understanding the dynamic alterations of cellular proteins for diagnostic and therapeutic 
options.  
In this study, it was demonstrated anticancer potentials (both cytotoxic and 
apoptotic effects) of Bortezomib on human MM U-266 cells. In addition to this, we 
have identified the differentially expressed proteins of U-266 cells when they exposed 
to Bortezomib with an enough concentration, for the first time. Because the function of 
the differential expressed proteins are of great importance for new targeted teurapautic 
options both Multiple Myeloma and other cancer types. 
In order to achieve our aims in the project, variety of multidisciplinary subjects 
came together. Cancer research techniques, biochemical studies and proteomics were 
combined. Protein profiling provides a much better understanding of an organism, in 
terms of structure and function. Use of protein profiling in the study of multiple 
proteins, protein forms, and protein families almost always by comparing two different 
states (diseased vs. healthy or treated vs. untreated) is expected to expand our 
understanding of molecular mechanisms. At the first experiment part, the cytotoxic 
effect was determined by measuring the IC50 value of Bortezomib at 72 h using XTT 
cell proliferation assay. It was calculated from cell proliferation plots and found to be 17 
nM. Then, apoptosis was evaluated by measuring the changes in caspase-3 enzyme 
 88 
 
activity and loss of mitochondrial membrane potential (MMP). Treatment of U-266 
cells for 72 h with 20 nM Bortezomib caused a significant loss of MMP (about 2.14-
fold), as measured by increased accumulation of cytoplasmic mitochondrial form of JC-
1 and also resulted in 1.17-fold increase in caspase-3 activity.  
After the 2D PAGE analysis, so as to elucidate and compare protein profiles of 
two groups at issue, two individual gel images were imported into gel analysis software 
DECODON Delta2D Version 4.3. With the help of software, these 2D PAGE gels were 
superposed and comparative detailed analysis was performed. According to the analysis, 
37 protein spots were differentially expressed. Among them, 5 proteins were newly 
formed, 10 proteins lost, 12 proteins were up-regulated and 10 proteins were down-
regulated as compared to control group (untreated cells). These differentiated proteins 
(increased and/or decreased or appear and/or disappear) were recovered from gel to be 
applied for MALDI-TOF Mass Spectrometry for protein identification and their 
function was evaluated. While sixteen proteins were not identified because of some 
personal and instrumental errors, twenty one of them were determined (it is considered 
that there were not seen two or more than peptide matches in the results). According to 
results, six proteins are related with cell signaling (Spot 7, 11, 14, 15, 23, 29), one 
protein has a role in cell survival (Spot 34), one is cell cycle regulator (Spot 4), two 
proteins are involved in apoptosis (Spot 2, 27), one protein is concerning tumor 
suppressor (Spot 8),five proteins take a key role in immunity and defense mechanism of 
the body (Spot 9, 12, 18, 25, 35), one protein is involved in protein modification and 
protein ubiquitination (Spot 22) and three of them has other functions (Spot5, 6, 10). 
For the further step studies, the same anti-cancer agent can be tried to treat other 
cancer types, with the help of differentially expressed proteins. Additionally, the data 
obtained by this study can be used to improve new treatments for Multiple Myeloma by 
drug designers.  
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APPENDIX A 
 
MEDIAS 
 
A.1. RPMI-1640 Growth Medium 
 
RPMI-1640, penicillin-streptomycin and fetal bovine serum (FBS) were 
obtained from Invitrogen (Paisley, UK). 
  
 60 ml FBS (~10% of all volume) and 
 10 ml Penicillin-Streptomycin (~1%) 
 
were added to  
 
 500 ml RPMI-1640 and mixed. 
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APPENDIX B 
 
CHEMICALS, REAGENTS AND SOLUTIONS 
 
B.1. Bortezomib 
 
Bortezomib was obtained from LCLabs (USA). The stock solution of 
Bortezomib was prepared in dimethyl sulfoxide (DMSO) at a concentration of 2,6 
mmol/ml (1,5 mg of Bortezomib was dissolved in 1 ml DMSO), stored at -20
o
C and 
diluted in cell culture medium. Molecular weight of Bortezomib is 384.24 g/mol. 
 
B.2. MM U-266 Cells 
 
U-266 human MM cells were kindly obtained from the German Collection of 
Microorganisms and Cell Cultures (Germany). 
 
Table B.1. Chemicals and Reagents Used in Experiments 
NO CHEMICALS COMPANY 
1 Dimethyl Sulfoxide (DMSO) Sigma 
2 Trypan Blue Dye Sigma 
3 Phosphate Buffered Saline (PBS) Invitrogen 
4 Penicillin-Streptomycin  Invitrogen 
5 Fetal Bovine Serum (FBS) Invitrogen 
6* XTT Reagent 
(should not be exposed to light) 
Biological Industries 
7* Activation Reagent 
(should not be exposed to light) 
Biological Industries 
8** DEVD-pNA  
(should not be exposed to light) 
(Stored at -20
o
C) 
BioVision 
9** Cell Lysis Buffer 
(Stored at +4
o
C) 
BioVision 
10** 2X Reaction Buffer 
(Stored at -20
o
C) 
BioVision 
11** Dithiothreitol (DTT) 
(Stored at -20
o
C) 
BioVision 
cont. on next page 
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Table B.1. Chemicals and Reagents Used in Experiments (cont.) 
12 Bovine Serum Albumine (BSA) Sigma 
13 Coomassie Brilliant Blue G-250  
(CBB G-250) Dye 
AppliChem 
14 Absolute Ethanol AppliChem 
15 Phosphoric Acid AppliChem 
 
16*** 
JC-1 Reagent  
5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine iodide 
(lyophilized) 
 
Cell Technology 
17*** 10X Assay Buffer Cell Technology 
18 Urea (8M) AppliChem 
19 Thiourea AppliChem 
20 Glycerol AppliChem 
21 Ampholites (3-10) (%0.2) Fluka 
22 Bromophenol Blue (%0.5) AppliChem 
23 CHAPS (%2) AppliChem 
24 Agarose AppliChem 
25 SDS AppliChem 
26 phosphoric acid  AppliChem 
27 Iodoacetamide Sigma 
28 Acrylamide  AppliChem 
29 Bisacrylamide AppliChem 
30 1.5 M Tris – HCl pH = 8.8 AppliChem 
31 Ammoniun Persulfate (APS)  Sigma 
32 Tetramethylethylenediamine (TEMED) Sigma 
 
 6,7* are XTT Cell Proliferation Kit Components, 
 8, 9, 10, 11** are Caspase-3 Colorimetric Assay Kit Components, 
 16, 17*** are APO LOGIX JC-1 Mitochondrial Membrane Potential Detection 
Kit Components. 
 
B.3. XTT Cell Proliferation Assay Kit 
 
XTT Cell Proliferation Assay Kit was obtained from Biological Industries, 
Israel. 
 105 
 
B.3.1. XTT Reaction Solution 
 
In order to prepare a reaction solution sufficient for a 96-well plate, XTT reagent 
was defrosted and the Activation reagent was immediately defrosted prior to use in a 
37
o
C bath. Then 0,1 ml Activation reagent was added to 5 ml XTT reagent. 
 
B.4. Caspase-3 Colorimetric Assay Kit  
 
Caspase-3 colorimetric assay kit was obtained from BioVision, (USA). 
 
B.4.1. 2X Reaction Solution 
 
DTT was added to the 2X Reaction Buffer immediately before use.  
 
 10 mM final concentration :Add 10 µl of 1.0 M DTT stock per 1 ml of  
2X Reaction Buffer. 
 
Table B.2. Preparation of 2X Reaction Buffer 
2X Reaction 
Solution 
 ml 
2X Reaction 
Buffer 
µl 
Dithiothreitol 
DTT 
µl 
 
1.0 
 
990 
 
10 
0,6 594 6.0 
 
B.4.2. Stock BSA Standard (1 mg/ml) 
 
0.01  g of BSA was dissolved in 10 ml PBS. 
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B.4.3. Standard Curve for BSA 
 
Table B.3. Absorbance Values for BSA Standards 
Concentrations 
(µg/µl) 
Absorbances 
(595 nm) 
1 0,1775 
2 0,182 
4 0,191 
8 0,209 
20 0,263 
40 0,353 
 
 
 
Figure B.3. Standard Curve for BSA 
 
 
 
 
 
Figure B.1. Standard Curve for BSA 
 
B.4.4. Coomassie Brilliant Blue G-250 (CBB G-250) Dye 
 
 100 mg Coomassie Brilliant Blue G-250 (CBB G-250)   
 50 ml Absolute Ethanol 
 100 ml 85% Phosphoric Acid 
 
The above-mentioned mass of CBB G-250 was weighed and dissolved in 50 ml 
of absolute ethanol. Then, 100 ml of 85% Phosphoric Acid was added to this solution. 
After the overall solution was filtered through filter paper, the filtered solution (~15-20 
ml) was diluted to 1 liter with ultrapure water and stored at 4
o
C. 
y = 0.1730 + 0.0045x 
R
2 
= 0.9966 
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B.5. APO LOGIX JC-1 Mitochondrial Membrane Potential Detection 
Kit 
 
APO LOGIX JC-1 Mitochondrial Membrane Potential Detection Kit was 
purchased from Cell Technology, USA.  
 
B.5.1. JC-1 Reagent 
 
The lyophilized vial was reconstituted with 500 μl DMSO to obtain a 100X 
stock solution. Following that, it was mixed by inverting several times at room 
temperature until contents were completely dissolved. Next, resuspended JC-1 reagent 
was aliquated in small amountssufficient for one day experimental work and stored at -
20
o
C. When it was used, it was diluated 1:100 in 1X Assay Buffer (100X JC-1 reagent 
to 1X) immediately prior to use. 
 
B.5.2. 10X Assay Buffer 
 
10X Assay Buffer were diluted 1:10 with ultrapure water (1 ml 10X Assay 
Buffer + 9 ml UP Water). 
 
B.6. 2D PAGE 
 
B.6.1. Isoelectric Focusing (IEF) 
 
B.6.1.1. Preparation of Rehydration Buffer 
 
 It was used for rehydration of strips. 
 This protocol was for including proteins in buffer. 
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Preparation of Rehydration Buffer 
Urea (8M) 4.8 g  
     Total  
                   =    10 ml 
    Volume  
CHAPS (%2) 0.2 g 
DTT (50 mM) 0.077 g 
Ampholites (3-10) (%0.2) 100 µl 
Bromophenol Blue (%0.5) 1-2 µl 
   
 For urea was increasing the volume of liquid when dissolved, firstly, it 
was dissolved in 4ml ddH2O. Then the other chemicals were added, total 
solution was measured to see its volume and the final volume was 
bringed to 10 ml. 
 Ampholites was diluted to 1X from the 10X stock concentration. The 
ampholites concentration in total volume is %0.2.  
 Nearly, 1-2 µl Bromophenol Blue (%0.5) was used just to have color in 
buffer. 
 
B.6.1.2. Preparation of Equilibration Buffer I and II Stock 
 
Equilibration Buffer I (20 ml) Equilibration Buffer II (20 ml) 
7.2 g / 20 ml Urea 7.2 g / 20 ml Urea 
0.4 g / 20 ml SDS 0.4 g / 20 ml SDS 
5 ml Ultrapura H2O 5 ml Ultrapura H2O 
5 ml 1.5 M Tris – HCl pH = 8.8 5 ml 1.5 M Tris – HCl pH = 8.8 
0.4 g / 20 ml DTT - 
4 ml Glycerol 4 ml Glycerol 
- 0.5 g / 20 ml Iodoacetamide* 
 
* Iodoacetamide should be added freshly. (in Day 3).  
 After preparation, Equilibration Buffer I was lifted to +4
o
C while Equilibration 
Buffer II was kept at -20
 o
C.  
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B.6.2. SDS PAGE 
 
B.6.2.1. Preparation of Separating Gel 
 
Separating Gel (%12) for 2D PAGE 
Acrylamide / Bisacrylamide (%30) 32 ml  
 
Total 
 
80 ml 
dH2O 26.8 ml 
1.5 M Tris – HCl pH = 8.8 20 ml 
SDS (%10) 800 µl 
Ammoniun Persulfate (APS) (%10) 400 µl 
Tetramethylethylenediamine (TEMED) 40 µl 
 
 33 ml Separating Gel was loaded for each gel. 
 
B.6.2.1.1. Preparation of Separating Gel Components 
 
STOCK REAGENT PREPARATION 
 
 
A.   
Acrylamide / Bisacrylamide ( 30% T, 2.67% C ) 
Acrylamide 146.0 g 
N, N’- Methylene-bis Acrylamide 4.0 g 
 (Preweighed Acrylamide/Bis 37.5:1 mixture may be substituted) 
 Distilled water to 500ml. Filter and store at 4°C in the dark. Maximum shelf 
life under these conditions is 30 days. 
 
B. 
1.5 M Tris- HCl, pH 8.8 
 54.45 g Tris base 
 150 ml. Distilled water 
 Adjusted to pH 8.8 with HCl, Distilled water to 300ml. Store at 4°C 
 
C. 
0.5 M Tris- HCl, pH 6.8 
 6 g Tris base 
 60 ml distilled water 
 Adjusted to pH 6.8 with HCl, Distilled water to 100ml. Store at 4°C 
 
D. 
10% (w/v) SDS 
 Dissolve 10 g SDS in 60 ml water with gentle stirring. Distilled water to 100 
ml. 
cont. on next page 
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STOCK REAGENT PREPARATION (cont.) 
 
E. 
10% Ammonium Persulfade (w/v) 
 Dissolve 100 mg ammonium persulfate in 1 ml distilled water 
 
 
 
 
 
 
 
 
F. 
Sample Buffer (SDS reducing buffer: 62.5 Mm Tris- HCl, pH 6.8, 20% Glycerol, 2% 
SDS, 5% β- Mercaptoethanol) 
Distilled water 3.0 ml 
0.5 M Tris- HCl, pH 6.8 1.0 ml 
Glycerol 1.6 ml 
10% SDS 1.6 ml 
β- Mercaptoethanol 0.4 ml 
0.5% (w/v) bromophenol blue (in water) 0.4 ml 
Total 8.0 ml 
 Dillute the sample at least 1:4 with sample buffer. Heat at 95°C for 4 minutes. 
 
 
 
G. 
5x Running Buffer (1x= 25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) 
Tris base 45.0 g 
Glycine 216.0 g 
SDS 15.0 g 
 Distilled water to 3 L. Do not adjust the pH with acid or base. Store at 4°C. 
Warm to 37°C before use if precipitation occurs. Dillute 300 ml 5x stock with 
1.2 L distilled water for one electrophoretic run. 
 To prepare 100 ml of 1X TGS buffer, 20 ml of 5X TGS buffer was diluted to a 
final volume of 100 ml with ultra pure water. 
 
B.6.2.2. Preparation of Overlay Agarose 
 
SDS Electrophoresis Buffer 
Tris Base 3.03 g 
Glycine 14.40 g 
SDS 1.0 g 
 were dissolved in 1000 ml of distilled water 
Overlay Agarose 
Agarose 0.50 g  
 stored at 4°C Bromophenol Blue 2.0 mg 
SDS Electrophoresis Buffer 100 ml 
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B.6.2.3. Preparation of In-Gel Digestion Chemicals 
 
 Ammonium Bicarbonate (100 mM) : 0.2 g of ammonium bicarbonate was 
dissolved in 20 ml of water. 
 Ammonium Bicarbonate (50 mM) : 2 ml of 100 mM ammonium 
bicarbonate was mixed with 2 ml of water. 
 DTT (10 mM) : 1.5 mg of dithiothreitol was placed in a 1.5 ml plastic 
centrifuge tube followed by addition of 1 ml of 100 mM ammonium 
bicarbonate for complete dissolving of DTT. 
 Iodoacetamide (100 mM) : 18 mg of iodoacetamide was placed in a 1.5 ml 
plastic centrifuge tube followed by addition of 1 ml of 100 mM 
ammonium bicarbonate for complete dissolving of iodoacetamide. 
 Trypsin Solution : 1 ml of ice cold 50 mM ammonium bicarbonate was 
added to 20 μg of sequencing-grade modified trypsin (V5111; Promega) 
and dissolved by drawing the solution into and out of the pipette. The 
trypsin solution was kept on ice until use. The final concentration is 20 
ng/ml trypsin. 
 Extraction Buffer : 10 ml of acetonitrile (Merck) was added to 5 ml of 
water followed by addition of 1 ml of formic acid (Merck) and the final 
volume was adjusted to 20 ml with water. The final concentrations were 
50 % (v/v) acetonitrile and 5 % (v/v) formic acid. 
 
B.6.2.4. Preparation of MALDI Matrix 
 
α-cyano-4-hydroxycinnamic acid (HCCA) was used as a matrix in proteomics 
studies and it was prepared with two layer method.  
First Layer : Approximately 3–6 mg of HCCA was weighted in 100 µl methanol 
(MeOH). Then 400 µl acetone was added to the mixture and dissolved all of them. 
Increase MeOH part on very dry days and lower it on very humid days. 
Second Layer : Approximately 5 mg of HCCA was weighted into a plastic vial 
and 200 µl MeOH was added. Firstly, all the matrices into MeOH were dissolved and 
than, 300 µl deionized water which contains 0.1% TFA was added. HCCA started to 
precipitate out. Finally, it was centrifugated at maximum speed for nearly 8 minutes. 
